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1 Introduction 
 
Over the past few decades, the importance of health-related quality of life (HRQoL) has 
become increasingly recognised in measuring the impact of chronic diseases in a number 
of fields of medicine, including dermatology. This interest is reflected in the growing 
number of studies published investigating the effect of various illnesses and health 
interventions on HRQoL. Currently the term ‘HRQoL’ yields over 27,000 hits in 
PubMed1.  
 Chronic skin diseases, such as psoriasis, eczema, vitiligo and pemphigus, have a 
profound impact on patients’ HRQoL, adversely affecting everyday activities, work, 
relationships and leisure time, among others. Additionally, in modern societies, where 
greater importance is attached to appearance and beauty, patients with visible lesions on 
the skin often experience stigmatisation, which may increase the risk of mental illness 
and social isolation [1, 2]. The assessment of HRQoL is widely used to explore the burden 
experienced by patients with chronic skin diseases in everyday clinical settings, as well 
as in various dermatological researches, including observational and interventional 
studies. In dermatology, a growing number of randomised controlled trials (RCTs) apply 
HRQoL measures as secondary or tertiary endpoints to evaluate treatment efficacy [3, 4]. 
This can be particularly informative when HRQoL does not correlate strongly with 
disease severity, for instance in psoriasis, hand eczema or alopecias [5-7]. Thus, HRQoL 
and severity scores complement each other in understanding individual patients’ health 
status as a whole and contribute to reaching optimal clinical decisions for each patient.  
 As HRQoL outcomes reflect patients’ perspectives about the burden of their skin 
disease, they thus engage patients as active partners in decisions related to their medical 
care. During the management of dermatological issues, several clinical decisions seem to 
be supported by information on HRQoL: diagnostic criteria, treatment choices, treatment 
monitoring or hospitalisation decisions. Besides its role in medical decision-making, 
assessing improvements in HRQoL with a therapy provides useful information for payers 
and policymakers about the benefits of certain treatments. Life years saved as the result 
of a treatment, and improvements achieved in HRQoL, are considered as two major 
                                                 
1 ‘Health-related quality of life’ - text-word search in PubMed on 24th January, 2016 
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outcomes. The availability of highly effective but very costly treatments in dermatology, 
such as biological drugs, is rapidly expanding, thereby exerting growing pressure on 
health budgets. Health interventions resulting in more benefits in terms of HRQoL (and 
life years saved) for the same or lower costs are deemed to be cost-effective in comparison 
to alternative treatments [8]. Moreover, choosing the right cost-effective options 
improves efficiency in the allocation of finite resources in healthcare and helps to 
maximise value for money for patients and society. 
 There exists a wide range of literature with a number of outcome measures which 
address HRQoL issues in various chronic skin diseases. Nonetheless, very few studies 
have been undertaken in this area in Hungary specifically, and in a broader sense Central 
and Eastern Europe. For reimbursement decisions, though, national guidelines on health 
technology assessments (HTAs) recommend collecting HRQoL values derived from 
national-level surveys [9].  
This thesis therefore seeks to investigate HRQoL in chronic skin diseases in 
Hungary, with a special focus on issues influencing clinical and financial decision-
making in healthcare. The first chapter provides a description of the two dermatological 
conditions covered, namely psoriasis and pemphigus, a brief overview of the key terms 
and definitions used and an introduction to the background of the assessment of HRQoL 
in dermatology.  
In the following chapters, new empirical findings are presented from three 
independent investigations, carried out by our research group in Hungary between 2012 
and 2015 [10-16]. First, a cross-sectional survey on health status and HRQoL among 
Hungarian moderate-to-severe psoriasis patients was conducted (‘Psoriasis study’). The 
second investigation (‘Pemphigus study’) is covered in two parts: a systematic literature 
review and a meta-analysis of HRQoL studies in pemphigus, as well as a valuation of 
utilities for pemphigus health states in the general population. The third research (‘DLQI 
study’) explores the relationship between a dermatology-specific HRQoL measure, 
namely the Dermatology Life Quality Index (DLQI), and health utilities within the 
framework of an Internet experiment carried out with members of the general public. 
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1.1 Description of the diseases covered in the thesis 
The disease-specific studies in this thesis focus on two chronic dermatological conditions, 
psoriasis and pemphigus. 
1.1.1 Psoriasis 
Aetiology and epidemiology 
Psoriasis is a chronic, inflammatory, immune-mediated condition with a complex 
aetiology of genetic and environmental risk factors [17, 18]. The prevalence of psoriasis 
varies across geographical regions, age groups and ethnicities [19]. In Europe, among 
individuals of all ages, the prevalence ranges between 0.73% and 2.9%, and incidence 
stands at about 120-140 out of 100,000 people [19]. No data are available from Hungary 
on the epidemiology of psoriasis. 
Comorbidities 
Psoriasis is often associated with multiple comorbidities, including psoriatic arthritis, 
inflammatory bowel diseases, diabetes, metabolic syndrome, obesity, dyslipidaemia, 
cardiovascular disease and psychological or psychiatric disorders [20, 21]. It is estimated 
that around 10-40% of all patients develop psoriatic arthritis [22]. Severe psoriasis 
patients may have an increased risk of mortality due to various causes, amongst which 
cardiovascular disease is the most common [23]. 
Clinical characteristics 
Five clinical types of psoriasis are known, among which chronic plaque psoriasis (i.e. 
psoriasis vulgaris) is the most prevalent. It is typically characterised by raised, well-
demarcated, erythematous plaques with adherent silvery scales. Primary predilection sites 
include elbows, knees and the scalp. It may remain localised or become generalised over 
time. Guttate (or eruptive) psoriasis is manifested in scaly teardrop-shaped spots. Inverse 
(or intertriginous) psoriasis usually develops in skin folds, such as armpits, the groin or 
inframammary folds. Pustular psoriasis is an uncommon variant, which can present as 
localised to the palms and soles (palmoplantar pustulosis) or become generalised. 
DOI:10.14753/SE.2016.1921
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Furthermore, erythrodermic psoriasis is a rare but severe form of the disease that can 
either develop acutely or follow a chronic course [24-27]. 
Diagnosis 
The diagnosis of psoriasis vulgaris is based primarily on clinical appearance and 
predilection sites. The removal of psoriatic scales may cause multiple fine bleeding 
points, known as Auspitz’s sign. Rarely, a histological examination of a skin biopsy is 
needed to confirm the clinical diagnosis [28]. 
Outcome measures 
The severity of psoriasis is classified into two main categories (mild and moderate-to-
severe) based on three outcome measures: body surface area (BSA), the Psoriasis Area 
and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) [29].  
The BSA percentage indicates how much of the body’s surface is affected by 
psoriasis. Traditionally, the patient’s palm is considered equal to 1% of BSA [30].  
PASI is a quantitative rating scale for psoriasis based on the severity of the lesions, 
judged on the coverage area and plaque appearance. To calculate PASI scores, the body 
is divided into four distinct regions based on the estimated area of the skin affected 
(head=0.1, upper extremities=0.2, trunk=0.3 and lower extremities=0.4). Each area is 
rated by itself from 0 to 6, where 0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 
5=70-89% and 6=90-100% involvement. The severity of plaques is graded by the 
presence of three clinical signs: erythema, induration and desquamation (measured on a 
scale of 0-4, with 4 being the worst). The total PASI score ranges from 0 to 72, with 
higher scores referring to greater disease severity [31-33]. 
The DLQI is a dermatology-specific HRQoL questionnaire validated for 
measuring HRQoL in psoriasis [34]. The ten-item questionnaire’s scale ranges between 
0 and 30, where higher scores indicate the worst disability experienced by patients. See 
the DLQI in detail in Chapter 1.3.2.4. 
DOI:10.14753/SE.2016.1921
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Based on these three outcome measures, mild plaque psoriasis is defined as (BSA 
≤ 10 or PASI ≤ 10) and DLQI ≤ 10, whereas (BSA > 10 or PASI > 10) and DLQI > 10 
suggests a moderate-to-severe disease (‘rule of tens’) [29, 35].  
Treatment 
The recommendations of the European S3-Guidelines on the treatment of psoriasis are 
based on disease severity [28]. Topical agents, including calcipotriol, corticosteroids, 
dithranol and calcineurin inhibitors such as tacrolimus, are used as first-line treatments of 
mild disease. In moderate-to-severe psoriasis patients, the following traditional systemic 
treatments are suggested: cyclosporine, methotrexate and psoralen combined with 
ultraviolet-A light (PUVA). Biological systemic treatment (adalimumab, etanercept, 
infliximab or ustekinumab) is recommended to a patient if conventional systemic agents 
have been inadequate in response, or if they are contraindicated or not tolerated [28].  
1.1.2 Pemphigus 
Epidemiology 
Pemphigus is a rare autoimmune disease blistering disease that may affect the skin and 
mucosa. It has an annual incidence of 0.1 and 7 per million [36]. The mean age of onset 
is usually between the ages of 50 and 60, but it can develop at any age. Other autoimmune 
conditions, such as myasthenia gravis and thyroid diseases, often develop in pemphigus 
patients [37, 38].  
Clinical forms 
Clinically, the two most common forms of pemphigus are pemphigus vulgaris (PV) and 
pemphigus foliaceus (PFo), which differ in their target antigens, the location of lesions 
within the epidermis as well as their symptoms. In Europe and the US, the most common 
clinical type is PV, whereas in Africa pemphigus foliaceus is more frequent [39]. In PV, 
autoantibodies are directed predominantly against desmoglein (Dsg)-3 together with 
Dsg1 of desmosomes (macula adherens), whereas solely Dsg-1 antibodies are produced 
in PFo. The regional expression pattern of the two antigens targeted by the autoantibodies 
is reflected in the location of skin lesions in different pemphigus forms. In PV, mucous 
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membranes, especially those of the oral cavity, are very frequently affected, because Dsg-
3 is expressed strongly in mucosae and weakly in the epidermis. In contrast, Dsg-1 is 
expressed mainly in the upper levels of the epidermis, just below the stratum corneum, 
but weakly in mucosae. Oral lesions are thereby not common in PFo. In PV, on the 
contrary, bullae develop just above the basal-cell layer, as Dsg-3 is present primarily in 
the deeper layer of the epidermis while absent in the superficial layer [39, 40]. 
Clinical characteristics 
Typically, PV begins with multiple, painful, non-healing ulcerations in the oral cavity. 
Other mucosae, such as the nasal cavity, pharynx, larynx, oesophagus, genital mucosae 
and the rectum, may as well be involved. The first skin symptoms may follow mucosae 
involvement weeks or even months later. The scalp and the torso are very commonly 
affected. Blisters are usually flaccid, and applying lateral pressure on the border of an 
intact blister results in the separation of the epidermis (positive Nikolsky’s sign). Skin 
lesions in the superficial form, PFo, usually manifest in multiple, pruritic and crusted 
erosions on the upper torso, face and the scalp. The crusts can be removed easily, leaving 
superficial erosions [39-41].  
Outcome measures 
A number of scoring systems have been developed and validated to quantify disease 
severity in pemphigus based on the global assessment of the lesions [42]. 
The Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) is a complex 
pemphigus scoring system that considers both the extent and the severity of cutaneous as 
well as oral pemphigus lesions. First, skin involvement is assessed by weighting the BSA 
(%) by the quality of the lesions. Weighting factors are as follows: erosive, exudative 
lesions or a positive Nikolsky’s sign 1.5, dry lesions 1.0 and re-epithelised lesions 0.5. 
Secondly, oral involvement is rated based on the presence of lesions on 11 different sites 
of the mouth. The severity of oral symptoms is scored by the pain or bleeding caused by 
certain foods (always=1, sometimes=0.5, never=0). The total score ranges from 0 to 150, 
where a higher score indicates greater severity [43]. 
DOI:10.14753/SE.2016.1921
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In the Pemphigus Disease Area Index (PDAI), the lesions are categorised in 
relation to the skin (12 body sites), the scalp (one body site) and mucous membranes (12 
areas). The skin and the scalp components consist of activity and damage scores. Activity 
scores are obtained based on the number of erosions, blisters or new erythema, whereas 
damage scores are given based on the presence of post-inflammatory hyperpigmentation 
or erythema from resolving lesions. The total score varies between 0 and 263, where 
higher scores indicate the worst disease severity [42, 44]. 
The Ikeda-index has four domains (affected area percentage, Nikolsky’s sign, 
daily number of new blisters and oral lesions in percentage), with each being scored from 
0 to 3. The sum total score of the four domains ranges from 0 (best) to 12 (worst) [45].  
Diagnosis 
The diagnosis of pemphigus is based on four independent criteria: clinical presentation, 
histopathology, direct immunofluorescence microscopy of perilesional skin and the 
serological detection of serum autoantibodies against epithelial cell surface antigens 
(Dsg-1 and Dsg-3) by indirect immunofluorescence microscopy and/or enzyme-linked 
immunosorbent assays [46]. 
Treatments 
If left untreated, the blisters and/or erosions spread, which can be potentially life-
threatening. With proper treatment, however, pemphigus usually heals without scarring. 
According to the European S2 Guideline for the diagnosis and treatment of pemphigus 
(2015), the current therapeutic algorithm includes systemic corticosteroids as a first-line 
treatment, followed by azathioprine, mycophenolat mofetil or mycophenolic acid as a 
second-line treatment. In refractory pemphigus patients, or when glucocorticoids and 
immunosuppressants are contraindicated, rituximab (anti-CD20 monoclonal antibody) 
intravenous immunoglobulins, immunoadsorption, cyclophosphamide, dapsone or 
methotrexate are recommended [46].  
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1.2 Key terms and definitions of the thesis 
1.2.1 Health-related quality of life  
The World Health Organization (WHO) defines quality of life as an [“individual's 
perception of their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns.”] [47]. 
Quality of life covers several domains of life, including physical health, psychological 
health, personal beliefs, social relationships and the environment.  
In medicine, the term ‘health-related quality of life’ (HRQoL) is preferred; 
however, it extends far beyond physical health alone. HRQoL comprises three core 
domains, namely physical, psychological and social, which interact with each other and 
are influenced by an individual’s experiences, beliefs, perceptions and expectations. Each 
incorporates many components; for example, the physical domain includes symptoms, 
disability and the ability to function, whereas the social domain refers to areas of work, 
daily role and personal relations. It is not hard to imagine, therefore, that the possible 
number of health states is almost infinite; two patients with the same diagnosis and 
severity scores may differ significantly in their HRQoL [48-50]. 
1.2.2 The concept of utility 
Utility is a cardinal measure of the desirability or preference that individuals exhibit for a 
given condition [51, 52]. The term refers to the von Neumann-Morgenstern utility theory 
for decisions under uncertainty [53], and it assumes that people strive to maximise a 
weighted sum of utilities, where the weights are probabilities and choices between 
gambles or lotteries containing goods and services. The following axioms undermine the 
theory, where A, B and C are lotteries [54]: 
 Transitivity: if lottery A is preferred or indifferent to lottery B, and B is preferred 
or indifferent to lottery C, then A is preferred or indifferent to C 
 Continuity: there is an indifference curve such that all points to its northeast are 
preferred to all points to its southwest 
DOI:10.14753/SE.2016.1921
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 Completeness: either lottery A is preferred to B, and lottery B is preferred to 
lottery C, in which case there is some combination of A and C that will be 
preferred to B 
 von Neumann-Morgenstern independence: adding a third lottery to two lotteries, 
whose ranking has already been determined, will not affect that ranking [54]. 
Utilities represent a widely used approach to the measurement of HRQoL. Utility 
values, or in other words HRQoL weights, can be assessed for any health state and reflect 
the HRQoL accordingly [52]. Generally, utilities are expressed in an interval scale 
anchored to 0 and 1, where 0 indicates death and 1 indicates perfect health. In many 
studies, however, health states can take a negative utility between zero and minus infinity, 
if judged as being worse than being dead [55].  
As HRQoL outcomes are used to help healthcare decision making, utilities are 
particularly appropriate measures of HRQoL, given their foundation in decision 
theory [52].  
1.2.3 Quality-adjusted life year 
The time spent in health states is weighted by the utility for health states to calculate the 
unit of quality-adjusted life year (QALY). Thus, QALYs combine the effects of a health 
intervention on mortality and morbidity into a single index. One QALY is equal to one 
life year in perfect health. It is a standard health outcome that permits the comparison 
between different health interventions for different diseases. The QALY is needed for the 
cost-utility analysis, which is a special form of cost-effectiveness analysis [56, 57]. The 
primary outcome of cost-utility analysis is the incremental cost-effectiveness ratio, which 
indicates the additional cost per QALY gained. When comparing alternative treatments, 
a health intervention that generates a lower cost per QALY ratio is preferred to that of a 
higher cost per QALY ratio [8].  
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1.3 Background to the assessment of HRQoL in dermatology 
1.3.1 Burden of chronic skin diseases 
The impact of dermatological diseases on patients’ HRQoL is very heterogeneous in 
terms of the affected domains and the magnitude of impairment. Some minor 
dermatological conditions, such as verruca vulgaris or onychomycosis, slightly influence 
HRQoL, whereas life-long chronic skin diseases, including psoriasis, may profoundly 
alter patients’ lives as a whole. Certain skin diseases reduce HRQoL, albeit only in 
individual domains; for instance, hand dermatitis leads to decreased HRQoL mainly in 
the domains of work and household activities [58]. In contrast, patients with rosacea 
experience the most problems in the mental health and social relationship areas [59]. In 
the most severe skin diseases, however, all dimensions can be adversely affected: daily 
routine, work, leisure time, social relationships, sex life, sports and sleeping [60]. 
A large selection of physical symptoms, such as pain, pruritus and fatigue, can be 
associated with skin diseases. These vary from minor irritation of the skin to severely 
painful lesions. Pruritus, a common and very unpleasant symptom present in many 
dermatological diseases, may lead to severe deterioration in HRQoL [61, 62]. 
Furthermore, many skin diseases are systemic conditions that impose an additional 
physical burden on patients; for instance, systemic sclerosis or psoriatic arthritis is often 
associated with restricted mobility. 
A special aspect of HRQoL in dermatology is that skin lesions, especially when 
manifested on the face, neck, hands or nails, are visible to others. The feeling of 
stigmatisation is very commonly reported among dermatological patients as a result of 
embarrassment, decreased self-esteem, psychological distress and the avoidance of social 
activities [63, 64]. It is therefore not surprising that anxiety, depression, suicidal ideation 
and many other mental health problems frequently occur in these patients [2, 65]. 
A recently advocated new concept, the Cumulative Life Course Impairment 
(CLCI) approach, suggests that the negative impact of chronic skin diseases on HRQoL 
cumulates throughout a patient’s lifetime [66]. The CLCI stems from a complex 
interaction between the burden of stigmatisation, physical and psychological impairment, 
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coping strategies and several external factors, such as social support [66-69]. As a result, 
in the long term, major life-changing decisions related to education, career choice, having 
children, getting married and travelling could be influenced by chronic skin disease [70, 
71]. 
The consequences of the limitations in HRQoL include the secondary negative 
impact on a patient’s family, work productivity and financial status. Skin disease can 
interfere with the family members and partners of patients in many ways, of which the 
burden of extra housework, psychological pressure (e.g. worrying about the patient), 
limitations to holiday plans, leisure activities and sexual relationships are very commonly 
mentioned concerns [72, 73]. 
Patients regularly miss working hours or whole workdays due to visits to 
physicians, treatments or the illness itself (absenteeism). The skin disease, however, may 
have a negative influence on work performance, too (presenteeism). In hand eczema or 
psoriasis, the physical burden of work or the regular irritation of the skin often force 
patients to quit their jobs. Patients with moderate-to-severe skin diseases are also more 
likely to be unemployed [74-77].  
The costs of skin disease, including co-payments (e.g. drugs, physician visits), as 
well as the cost of transportation to physicians and caregivers places a great financial 
burden on patients [78-80]. High costs can be attributed to cosmetic products, careful 
choices of clothing and other devices (e.g. wigs for alopecia patients). Furthermore, the 
household income of patients with severe skin diseases may be significantly reduced [81, 
82]. 
1.3.2 Methods employed to assess HRQoL and utilities in dermatology 
This section provides a brief overview of the most commonly used HRQoL tools in 
dermatology. Special emphasis is given to those involved in the original researches of 
this thesis. The domains and scoring for all HRQoL instruments related to this thesis are 
detailed in Appendix 12.1. 
In general, HRQoL measures aim at detecting changes in HRQoL and 
discriminate between patients who have a better and those who have a worse HRQoL. 
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There are no best or worst instruments – the choice of the instrument usually depends 
upon the purpose of the study, the condition studied, the characteristics of the study 
population (e.g. age, health status and language) and the method of data collection (e.g. 
clinical trial, outpatient visit, postal or Internet survey) [83].  
There are two basic approaches to the assessment of HRQoL: preference-based 
and non-preference based methodologies (Figure 1). The difference between these two 
large groups of methodologies is the ability to provide utility values. Only preference-
based instruments enable one to calculate utility values, and thus they can be used in 
economic evaluations. Non-preference-based measures, nevertheless, are widely used in 
clinical trials to explore changes to HRQoL across several dimensions. A variety of non-
preference based instruments exist, and these either cover all aspects of patients’ lives 
that an illness can affect (generic instruments) or are specific to a group of diseases 
(dermatology-specific instruments) or to individual diseases (disease-specific 
instruments) [84]. 
Preference-based measures are generally classified into direct and indirect 
methods of utility assessment. In direct methods, patients or members of the general 
public value hypothetical or experienced health states. In indirect methods, patients 
complete a multidimensional HRQoL questionnaire, and then a tariff obtained from the 
general population is used to transform the patients’ answers into utility weights [85-87]. 
Of course, patients know their disease best; yet, people who experience a certain disorder 
tend to rate it as less severe than people who do not have it [88]. Some reasons identified 
to contribute to this discrepancy include: i) patients and the general public may understand 
the health state vignettes differently; ii) general population members may not consider 
adaptation to health states; iii) a response shift in how people rate health states as a result 
of getting ill or changing expectations and iv) focusing illusion, whereby people forget to 
consider obvious aspects of unfamiliar health states [87]. Therefore, utility values are 
somewhat influenced by the populations who elicit them in the first place.  
DOI:10.14753/SE.2016.1921
  
 
 
1
7 
 
 
Figure 1 Measurement of HRQoL in dermatology 
* VAS, TTO and SG are so-called ‘direct preference elicitation methods’, although VAS is not preference-based. 
ABQOL = Autoimmune Bullous Disease Quality of Life questionnaire; DLQI = Dermatology Life Quality Index; DQOLS = Dermatology Quality of Life Scales; DSQL 
= Dermatology-specific Quality of Life; HUI = Health Utilities Index; KMPI = Koo-Menter Psoriasis Instrument; PDI = Psoriasis Disability Index; PQOL = Psoriasis 
quality-of-life questionnaire; SF-6D = Short form 6 dimensions; SF-36 = Medical Outcomes Study 36-Item Short Form; SG = standard gamble; SPI = Simplified Psoriasis 
Index; TABQOL = Treatment of Autoimmune Bullous Disease Quality of Life questionnaire; TTO = time trade-off; VAS = visual analogue scale 
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In countries with publicly-funded healthcare systems, the allocation of healthcare 
resources should, or would be expected to, take into account social preferences. Based on 
this notion, in many jurisdictions, HTA agencies such as the US Public Health Service 
Panel on Cost Effectiveness in Health and Medicine [89], the National Institute for Health 
and Care Excellence (NICE) [90] in the UK and the Canadian Agency for Drugs and 
Technologies in Health (CADTH) [91] recommend that utility values should be based on 
the preferences of the adult general population, rather than on patient preferences. 
Similarly, in Hungary, HTA guidelines provided by the Ministry of Human Resources 
promote the use of such utility weights in economic analyses of health technologies [9]. 
1.3.2.1 Direct utility assessment 
There have been three major direct techniques developed to elicit utility values: the visual 
analogue scale (or rating scale), standard gamble (SG) and time trade-off (TTO).  
Visual analogue scale 
The visual analogue scale (VAS) is a graphical form of rating scales. A typical VAS 
consists of a straight, vertical or horizontal line with two clearly defined endpoints. These 
endpoints are usually marked with labels corresponding to ‘best imaginable health state’ 
(or ‘perfect health’) and ‘worst imaginable health state’ (or ‘being dead’). Numbers may 
also be used as anchors; for example, 100 or 10 or 1 often represent the most preferred 
outcome, whereas 0 is the least preferred option. Subjects are asked to mark their rating 
of a health state on the scale, which in most cases lies between the two anchors [51, 52]. 
Simplicity and the easiness of administration make VAS a very attractive 
instrument. However, it is often considered inferior to TTO and SG, because these both 
require respondents to express their preferences about health states and to make decisions 
that have an opportunity cost in the form of sacrificed life years in the TTO task or the 
certainty of survival in SG [92, 93]. 
Standard gamble 
The standard gamble (SG) method is based directly on the von Neumann-Morgenstern 
utility theory. In SG exercises, subjects are offered two options. They can choose between 
the certainty of remaining in an impaired health state for a defined time duration or they 
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can take a risk of either regaining perfect health (probability p) or facing immediate death 
(probability 1-p). The probability of immediate death is varied until the subject becomes 
indifferent in relation to the two alternatives. At this point the utility for the impaired 
health state is equal to the probability of regaining perfect health (p) [51, 52, 94, 95].  
In the field of dermatology, the SG methodology has been applied successfully in 
atopic dermatitis, psoriasis, scleroderma and melanoma [96-100].  
Time trade-off 
The time trade-off method (TTO) is the most frequently applied approach for the direct 
assessment of utilities [101]. The methodology was developed specifically by Torrance 
[95] for use in healthcare settings. In TTO, subjects are asked to choose between two 
alternatives: living a longer period of time in a worse health state or a shorter period in a 
better health state (perfect health or the absence of a given disease). The amount of time 
offered in perfect health varies until the subject becomes indifferent in relation to the two 
options. Utility values for the impaired health state are calculated by dividing the number 
of years in perfect health by the number of years in impaired health [51, 52, 94, 95]. 
No uniform methodology currently exists to value health states by TTO; studies 
can differ considerably regarding many aspects, such as mode of administration, time 
frame, visual aids used, iteration procedure, definition of the best and worst health states 
and the subjects who elicit utilities (e.g. patients or general population) [102, 103]. 
Increasing numbers of studies apply the TTO methodology for dermatological 
research [104, 105]. In 2004, Chen et al. provided a preliminary repository of utilities in 
17 dermatological conditions by conducting TTO interviews at three dermatologic clinics 
in the US [106]. Besides, a few studies of individual diseases were undertaken in 
psoriasis, atopic dermatitis, scleroderma, acne, port-wine stain and melasma [98, 100, 
107-109].  
1.3.2.2 Indirect utility assessment: multi-attributable utility measures 
Multi-attribute utility (MAU) instruments are generic or disease-specific HRQoL 
questionnaires which consist of a descriptive or a self-classification system, including a 
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series of HRQoL items, together with a scoring algorithm. Responses can be either 
aggregated into dimension scores or subscale scores to establish the responder’s health 
profile, or they can be transformed into a single utility score by the scoring algorithm. 
These algorithms, often so-called ‘tariffs’ or ‘weights’, are usually obtained from a 
general population sample by a direct elicitation method (e.g. VAS or TTO) [110-112].  
The main advantages of MAU instruments are that they are flexible and easy to 
administer; however, the utility scores generated may depend largely on the algorithm 
used. There are six generic MAU measures that dominate the literature: the Quality of 
Well-being Index (QWB), 15 dimension instrument (15D), EuroQol-5-dimensions (EQ-
5D), the three versions of the Health Utilities Index (HUI 1-3), Short form 6D (SF-6D) 
and Assessment of Quality of Life (AQoL-8D). Of these, the EQ-5D is by far the most 
commonly employed tool [110-112]. 
EQ-5D 
EQ-5D is a five-item MAU instrument that assesses health status across five domains: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression [113, 114]. 
Each domain has three response levels (no problems, some problems, severe problems), 
and accordingly 35=243 combinations of health states are possible. A series of country-
specific scoring algorithms is available to calculate EQ-5D index scores (i.e. utility), but 
no Hungarian tariff has been developed, to date. It is accompanied by a visual analogue 
scale (EQ VAS) that is a 20 cm-long, vertical visual analogue scale with endpoints of ‘0’ 
(worst possible health state) and ‘100’ (best possible health state) recording patients’ self-
rating of their overall health, which also enables determining utilities.  
The EQ-5D has been translated into over 170 languages, it is cognitively simple 
and takes only a few minutes to complete [115]. Over the past two decades, population 
health surveys using the EQ-5D have reported population reference values from some 20 
countries [116]. In Hungary, two large sets of population norms are available, and the 
data collection periods for these were in 2001 and 2010 [117, 118]. 
In some countries, such as the UK and the US, the EQ-5D has become a favoured 
measure of utilities for economic analyses [89, 90]. Similarly, current HTA guidelines in 
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Hungary advocate the use of indirect measures, particularly the EQ-5D, to derive utility 
values [9]. 
A recent systematic literature review concluded that the EQ-5D has good validity 
and responsiveness in patients with skin disease, especially in plaque psoriasis [119]. To 
date, it has been applied in many skin conditions other than psoriasis, such as acne, atopic 
dermatitis, hand eczema, herpes zoster, hidradenitis suppurativa and venous leg ulcers 
[119, 120]. However, only two studies can be found in the literature utilising the EQ-5D 
in Hungarian patients with dermatological conditions, and these concentrate on psoriatic 
arthritis and scleroderma [121, 122].  
1.3.2.3 Generic profile instruments (non-preference-based) 
Generic measures were designed to give a general overview of HRQoL. The main 
advantage of these instruments is that they allow comparisons among different 
populations regardless of the underlying condition. Commonly used non-preference-
based generic profiles are the Sickness Impact Profile (SIP), Medical Outcomes Study 
36-Item Short Form (SF-36), the Nottingham Health Profile (NHP) and the Dartmouth 
Primary care Cooperative Information Project (COOP) [48, 83, 123]. 
SF-36 
The Short form 36 (SF-36) is the most commonly used and validated generic profile 
measure of health status in dermatological research [124]. It includes 36 items on a Likert-
scale format to assess the following eight dimensions of health: physical functioning (PF), 
role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social 
functioning (SF), role-emotional (RE) and mental health (MH). Scores on each domain 
range from 0 to 100, with higher scores indicating a better health state. The PF, RP, BP 
and GH subscales are summarised into a Physical Component Summary (PCS) score, and 
VT, SF, RE and MH to a Mental Component Summary (MCS) score [125, 126].  
General population norms for SF-36 are available from many countries that show 
the typical levels of HRQoL in these eight domains. In light of comparisons between 
patients and population reference values, physicians as well as payers can understand 
which domains of HRQoL are impaired – and to what extent – for a given condition. To 
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date, SF-36 has been employed in almost every chronic dermatological condition, 
including psoriasis, atopic dermatitis, contact dermatitis, chronic urticaria, pemphigus, 
acne, rosacea, alopecias and vitiligo [58, 59, 124, 127, 128].  
1.3.2.4 Dermatology-specific HRQoL measures 
Dermatology Life Quality Index 
The Dermatology Life Quality Index (DLQI) is the most commonly used HRQoL 
instrument in the field [3, 34, 129]. The questionnaire contains ten items, each of which 
is scored from 0 to 3, where 0 - not at all ⁄not relevant, 1 - a little, 2 - a lot, and 3 - very 
much. The results of each item are summed into a total score ranging from 0 (best health 
state) to 30 (worst health state). A banding system helps the interpretation of scores 
developed by Hongbo et al. [130]. A DLQI score of 0-1 has been interpreted as ‘no effect 
on patient’s life’, 2-5 as ‘small effect’, 6-10 as ‘moderate effect’, 11-20 as ‘very large 
effect’ and 21-30 as ‘extremely large effect’ [130]. 
In the past two decades, it has developed into a valid and reliable tool for HRQoL 
assessment in a variety of dermatological conditions [129]. Its advantages include brevity, 
easiness to administer and multilingual availability. So far, the DLQI has been used in 
over 30 different dermatological conditions [3]. The most common applications are 
psoriasis, atopic dermatitis, vitiligo, urticaria, contact dermatitis and acne [3, 129]. 
Its appropriateness as an outcome measure, however, has been disputed by many. 
A few studies have argued that factor-analysis and Rasch-analysis question the 
unidimensional construct of the DLQI, thereby suggesting that certain items of the 
measure are not independent [131-135]. It has been also addressed that it exhibits 
differential item functioning, in that the results are biased by the age, gender, disease, and 
nationality of patients [132, 133, 136]. 
Skindex 
Skindex-29 is a validated dermatology-specific HRQoL measure comprising three 
subscales: symptoms (seven items), emotions (10 items) and functioning (12 items). Item 
responses are transformed to a scale from 0 (no effect) to 100 (maximum effect), and 
subscale scores are calculated as the average of the patients’ responses to the items in a 
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given domain [137]. Two brief versions of Skindex-29 exist: Skindex-17 and Skindex-16 
[138, 139].  
Skindex instruments have been applied in a series of chronic dermatological 
conditions, both in observational and interventional studies: acne, actinic keratosis, atopic 
dermatitis, fungal diseases, hand dermatitis, hyperhidrosis, psoriasis, rosacea, scalp 
dermatitis and vitiligo [124, 140].  
1.3.3 Use of HRQoL measures in dermatology 
The assessment of HRQoL in dermatology is driven by multiple purposes, including 
clinical, research, economic and financial. 
Clinical  
In many chronic skin diseases HRQoL does not always correlate with disease severity  
[5-7]. Thus, disease severity measures alone are insufficient to capture the entire burden 
of skin diseases, and HRQoL and severity scores are suggested to be measured together, 
in order to provide a clear picture of an individual patient’s health status. Population 
norms are available for many instruments that allow one to compare a patient’s HRQoL 
to the reference values of the general population. This comparison outlines which 
domains of HRQoL are particularly impaired in a patient, and to what extent [141, 142]. 
Currently, information on the HRQoL of dermatologic patients is embedded in 
clinical decision-making in many ways: diagnostic criteria, treatment choices, treatment 
monitoring and decisions about admission to hospital. However, the contribution of 
HRQoL data to medical decisions varies according to diagnosis, disease severity and the 
type of treatment. HRQoL outcomes are the most explicitly present in the management 
of moderate-to-severe psoriasis, where diagnostic criteria include a dermatology-specific 
HRQoL tool, namely the DLQI. In psoriasis, (BSA>10 or PASI>10) and DLQI >10 can 
be considered a moderate-to-severe disease, and it is recommended to be treated with 
phototherapy or systemic treatments including biologicals (see in details: Chapter 1.1.1) 
[22, 23]. The European-S3 Guidelines on the systemic treatment of psoriasis vulgaris lists 
HRQoL among the outcomes required to be measured before and during systemic therapy 
[28]. More specifically, DLQI, Skindex-29 or -17 are among the instruments suggested 
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to be administered. In judging treatment response, a DLQI < 5 or, alternatively, a DLQI 
improvement of at least five points is often considered a minimum efficiency goal of 
systemic therapy [28].  
Similarly, European guidelines on the treatment of atopic dermatitis and acne 
promote the assessment of HRQoL [143, 144]. Nevertheless, no specific tool or severity 
score is proposed. In these conditions, therefore, the role of HRQoL in clinical decisions 
is more uncertain compared to that in psoriasis. This is well-exemplified in the European-
S3 guidelines for the treatment of acne, which states the following about the necessity of 
measuring HRQoL: [“The impact of acne on quality of life can be measured using 
general health measures, dermatology-specific measures or acne-specific measures.] … 
[Quality of life measures can influence the choice of therapy. In patients with a severe 
impact on their quality of life, a more aggressive therapy may be justified.”] [143]. 
Research 
HRQoL measures are used in epidemiologic as well as in clinical research. A large 
number of different dermatology- and disease-specific measures are available for 
dermatological researches. These may differ in how they define HRQoL, their domains, 
the amount and quality of psychometric testing and validation [145]. There have been a 
number of sharp debates as to which HRQoL instruments should be used in dermatology 
[124, 131-134, 136, 146, 147].  
A review by Both et al. provides a detailed comparison of generic health profiles 
and dermatology-specific questionnaires in terms of psychometric properties, scoring, 
administrative burden, respondent burden and cultural and language adaptations. This 
intends to help researchers to make an evidence-based choice of instrument that fits for 
the purposes and design of the study [124]. The choice of instrument transpires to be even 
more important, as HRQoL has become an accepted outcome measure of clinical efficacy 
in RCTs [3]. In psoriasis, for example, the European Medicines Agency recommends the 
use of DLQI as a secondary or tertiary endpoint to assess the efficacy of treatment [148]. 
It is also being used increasingly by many RCTs in atopic dermatitis [4]. Along with the 
DLQI, Skindex instruments are used in more and more RCTs across many skin 
conditions, including psoriasis, atopic dermatitis and acne [140]. What is more promising, 
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though, is that growing numbers of psoriasis RCTs apply preference-based HRQoL 
measures, such as the EQ-5D [149-151]. In psoriasis, this trend apparently coincides with 
the development of biological drugs. In other chronic dermatological diseases, however, 
there is a paucity in the administration preference-based instruments in RCTs [4, 152]. 
Economic 
HRQoL data assessed with preference-based instruments can be used for the calculation 
of QALYs in cost-utility analyses of health interventions (see details in Chapter 1.2.3). 
In non-life-threatening chronic skin diseases, the improvement in HRQoL following 
treatment is responsible for the majority of the QALY gain. Thus, the accurate 
measurement of HRQoL with respect to the choice of instrument, study design and patient 
population is crucial, as it has a direct impact on the outcomes of economic evaluation.  
Over the past decade, the number of cost-utility analyses published on 
dermatological treatments has been rising. Studies include tacrolimus [153], 
pimecrolimus [154, 155] and prebiotics for atopic dermatitis [156] and oral alitretinoin (a 
derivative of vitamin A) for severe chronic hand eczema [157]. Nevertheless, treatments 
for psoriasis, more specifically biological drugs, represent by far the most studied area. A 
recently published systematic review of cost-effectiveness analyses in psoriasis identified 
15 cost-utility examples in the literature [158]. The treatments studied were as follows: 
calcipotriol, calcipotriol and bethamethasone, methotrexate, ultraviolet B phototherapy 
and biological drugs [158]. 
Financial 
In several countries, dermatology-specific HRQoL measures, such as DLQI and Skindex, 
are used in national reimbursement guidelines to determine whether a patient should be 
considered for treatment. Examples include the financing of biological therapy for 
moderate-to-severe psoriasis and oral alitretinoin for severe chronic hand eczema [159].  
In the UK, Sweden, Denmark and six Central and Eastern European countries, 
including Hungary (Table 1), reimbursement criteria on financing biological therapy for 
moderate-to-severe psoriasis patients are based on DLQI scores alongside PASI and BSA 
[148, 160, 161]. Severity scores eligible for reimbursement vary across jurisdictions. In 
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the UK, for example, patients who accomplish PASI ≥10 and DLQI>10, in Hungary 
PASI>15 and DLQI>10 or in Croatia PASI>15 and/or BSA>15 and/or DLQI>15 are 
entitled to be treated with biologicals. In the Netherlands, Skindex-29 scores are used 
instead of DLQI in reimbursement criteria, whereby patients with PASI > 10 or (PASI > 
8 and Skindex-29 > 35) qualify for biological therapy [161]. 
Not only the initiation of biological therapy, but also eligibility for maintenance 
therapy is decided based on DLQI scores. In most Central and Eastern European 
countries, maintenance therapy is allowed for patients who reach a response of ≥50% 
reduction in PASI, and in addition a ≥5-point improvement in DLQI (Table 1) [148]. 
Table 1 DLQI in biological reimbursement eligibility criteria for psoriasis in 
Central and Eastern European countries 
 
Clinical severity criteria for being 
eligible to start covered biological 
therapy 
Criteria of eligibility for maintenance 
therapy (at week 12) 
Bulgaria PASI >20 or BSA>20 
PASI improvement ≥75%; or PASI 
improvement ≥50% and DLQI improvement 
≥ 5 points 
Croatia 
PASI >15 and /or BSA>15 and/or 
DLQI>15 
PASI improvement ≥50% and DLQI 
improvement ≥ 5 points 
Czech 
Republic 
PASI>10 and DLQI>10 PASI improvement ≥50% 
Hungary PASI>15 and DLQI>10 
PASI improvement ≥50% and  
DLQI improvement ≥ 5 points 
Poland PASI>18, DLQI>10, and BSA>10 
PASI improvement ≥50% and  
DLQI improvement ≥ 5 points 
Romania PASI ≥ 10 and DLQI≥10 
PASI improvement ≥50% and 
 DLQI improvement ≥ 5 points 
BSA = body surface area; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area and Severity 
Index  
Source: Rencz et al. 2015 [148]  
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2 Objectives 
2.1 Psoriasis study 
The objectives of this cross-sectional study were:  
1. To evaluate the health status and HRQoL of adult moderate-to-severe psoriasis 
patients in Hungary, to explore differences in HRQoL among subgroups of 
patients and to compare EQ-5D results to general population norms in Hungary; 
2. The assessment of patients’ subjective life expectancy (LE) and expected HRQoL 
for six months ahead and for future ages of 60, 70, 80 and 90, respectively.  
2.2 Pemphigus study 
Systematic review and meta-analysis of HRQoL studies 
Our aims were: 
1. To conduct a systematic review of the existing literature on the impact of 
pemphigus on HRQoL; 
2. To perform a meta-analysis on the outcomes of the most frequently used HRQoL 
instruments; 
3. To identify the possible determinants of HRQoL in pemphigus. 
Valuation of pemphigus health states by the general population 
This study aimed: 
1. To elicit utility values for hypothetical pemphigus vulgaris and pemphigus 
foliaceus health states, using two direct methods, VAS and TTO, in a general 
population sample.  
2. To compare the utilities assigned to different pemphigus health states. 
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2.3 DLQI study 
The objectives of the study were: 
1. The estimation of utilities for different health states described by the 10 items of 
the DLQI by the TTO method; 
2. To compare utility values elicited for health states with identical and different 
DLQI total scores. 
  
DOI:10.14753/SE.2016.1921
 29 
 
3 Methods 
3.1 Psoriasis study methods 
3.1.1 Study design 
A cross-sectional questionnaire survey of consecutive adult psoriasis patients from two 
Hungarian university clinics was carried out between September 2012 and May 2013. 
The study protocol was approved by the Scientific and Research Ethics Committee of the 
Medical Research Council of Hungary (ETT TUKEB), reference No. 35183/2012-EKU. 
We planned to enrol approximately 100 patients from each clinic. Patients of 18 years of 
age or over, who were diagnosed with moderate-to-severe psoriasis (PASI > 10 or DLQI 
> 10, or being treated by systemic or biological therapy) at least 12 months before the 
time of the survey, were included in the study. Data were collected by dermatologists 
during outpatient visits at Semmelweis University, Department of Dermatology, 
Venereology and Dermatooncology (Budapest) and at the University of Debrecen, 
Departments of Dermatology and Dermatological Allergology. Written informed consent 
was obtained from all patients [162, 163].  
3.1.2 Outcome measures and assessment 
Patients and their physicians were asked to complete a self-designed 
questionnaire. The patients’ questionnaire consisted of demographic data, the family 
history of psoriasis, disease duration, affected body sites and HRQoL measures. HRQoL 
was captured by the validated Hungarian versions of EQ-5D-3L descriptive system 
(hereinafter EQ-5D) and visual analogue scale (EQ VAS) and a dermatology-specific 
measure, namely the DLQI. The description and scoring of EQ-5D and DLQI are outlined 
in Chapter 1.3.2. We applied the UK tariff to calculate EQ-5D index scores (range -0.594 
to 1). Further questions concerned visit(s) to a general practitioner in the last month, to a 
dermatologist in the last three months and hospitalisation(s) in the last 12 months (all due 
to psoriasis). The necessity of home help in the last month and work impairment due to 
psoriasis were also recorded. In the second part of the questionnaire, dermatologists were 
asked to provide data on the clinical type of psoriasis and treatments in the last 12 months 
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based on medical records. PASI was used to assess the severity of psoriasis. PASI is 
described in detail in Chapter 1.1.1.  
3.1.3 Measuring patients’ expectations 
To elicit patients’ future expectations, we employed the descriptive system of the EQ-5D 
instrument, as was done previously in two large surveys on the general population in the 
Netherlands and Hungary, as well as in a recent study with Hungarian rheumatoid arthritis 
patients [164-166]. As the EQ-5D is set up to measure current health, we modified the 
time frame. Patients were asked to indicate the HRQoL they expected to have at six 
months ahead and at the age of 60, 70, 80, and 90 years, respectively (Table 2). The 
rationale behind the choice of six months was that this duration was assumed long enough 
to result in a considerable improvement in HRQoL following successful therapy, but short 
enough to be easily conceived. 
Table 2 Modified EQ-5D-3L to evaluate expectations regarding future HRQoL 
I think at age 60 I will have… (Please mark your response) 
a. 
no some major 
problems with walking about. 
   
b. 
no some major 
problems with washing or dressing. 
   
c. 
no some major problems with performing usual 
activities.    
d. 
no some severe 
pain or discomfort. 
   
e. 
no some severe 
anxiety or depression. 
   
*Ages 70, 80 and 90 were asked in the same construct 
We measured a point estimate of subjective life expectancy (LE) for each patient 
by asking them, “To what age do you expect yourself to live?” Patients were instructed 
not to answer questions about future ages they had already reached, and the responses of 
those who answered in spite of the request were excluded. The responses of patients who 
indicated an age higher than 100 years were truncated to 100. 
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3.1.4 Statistical analysis 
First, descriptive statistics of sociodemographic and clinical characteristics of the sample 
are presented. As the distribution of data was skewed, non-parametric statistics 
(Wilcoxon signed-rank test, Mann-Whitney U test and Kruskal-Wallis test) were used. 
Spearman’s correlations were applied to analyse the relationship between continuous 
variables, such as actual and expected EQ-5D index score, EQ VAS, DLQI, PASI, 
subjective LE and HRQoL expectations. A Spearman’s rank coefficient (rs) of 0-0.19 is 
defined as very weak, 0.20-0.39 as weak, 0.40-0.59 as moderate, 0.60-0.79 as strong and 
0.80-1 as a very strong correlation [167].  
EQ-5D results, in terms of both dimension percentages and index scores, were 
compared with the Hungarian general population norm published by Szende and Németh 
in 2003 [118]. Patients who did not indicate their subjective LE, their actual EQ-5D or 
their expected EQ-5D for six months were excluded from the analysis of expectations. 
For all respondents, we calculated the difference between their gender- and age-specific 
statistical life expectancy (actual LE) based on their subjective LE and data retrieved from 
the Hungarian Central Statistical Office (KSH) [168]. We computed the difference in 
HRQoL expectations between patients expecting to be alive at a given age (‘survivors’) 
and those not expecting to live (‘non survivors’). Finally, expectations on HRQoL for 
older ages were compared to the actual health statuses of the age-matched psoriasis 
patients within the sample. All the applied statistics were two-sided with a significance 
level of p<0.05. Statistics were performed with IBM SPSS version 20.0 (SPSS Inc., 
Chicago, IL, USA).  
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3.2 Pemphigus study methods 
3.2.1 Systematic review of HRQoL studies in patients with pemphigus 
3.2.1.1 Search strategy 
A systematic search was conducted using the following databases from their inception to 
6 October, 2014: Ovid Medline, EMBASE, Web of Science, CINAHL, PsycINFO, and 
the Cochrane Library. The search strategy (Appendix 12.2) designed for this study 
included a combination of terms related to pemphigus, general HRQoL terms, names of 
generic and dermatology-specific instruments and HRQoL assessment methods based on 
the recommendations of Paisley et al. [169]. The search excluded publications of the 
following types: comments, editorials, letters or conference papers. No language limits 
were applied. In addition, the references of all included studies were searched for eligible 
studies. Review articles were excluded; however, their reference lists were also examined 
for relevant studies. 
3.2.1.2 Selection of the studies 
Titles and abstracts of the identified records were screened by two independent 
researchers (Fanni Rencz and Valentin Brodszky). Any disagreement was resolved 
through discussion until consensus was reached. Only records meeting the following 
inclusion criteria were selected for a full-text review:  
 The study population included adult pemphigus patients;  
 The study reported HRQoL in pemphigus patients assessed by any instrument;  
 Publication type: original article not a review or a conference abstract or 
proceeding.  
During the full-text review, all papers meeting any of the following criteria were 
excluded:  
 No HRQoL outcome reported;  
 Only aggregate HRQoL values were available for a group of skin diseases;  
 Full-text article not available. 
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3.2.1.3 Data extraction  
The following data were extracted from all included studies: patient characteristics 
(sample size, pemphigus type, mean age, disease duration, sex ratio, current therapy, and 
geographic location), applied HRQoL instruments, HRQoL scores and determinants of 
general or dermatology-specific HRQoL analysed statistically in the studies. We 
considered significant the relationship between determinants and HRQoL, if a significant 
unidirectional relationship with HRQoL was justified in ≥2 studies. 
3.2.2 Meta-analysis 
For meta-analysis, the number of patients, mean HRQoL scores and standard deviations 
(SD) were extracted from each study, and 95% confidence intervals were calculated. 
Where SD was not reported, we replaced it by the average SD of the other studies.  
Meta-analysis was carried out on total scores or individual domains of HRQoL 
instruments on which results were reported in at least three separate studies including 
patients of similar characteristics. Data were pooled by using the inverse-variance 
weighted method. Heterogeneity across studies (i.e. variability in HRQoL as a 
consequence of clinical and methodological diversity) was analysed using the Cochran’s 
Q and the I2 statistics [170]. Where significant heterogeneity was detected across studies 
(Cochran’s Q<0.01 or I²>50%), a random-effects meta-analysis (DerSimonian and Laird 
method) was applied [171]; otherwise, a fixed-effects model was employed. In random-
effects meta-analysis it is assumed that each study is derived from a different population 
of patients; therefore, the true effect size is not identical in all studies, though they do 
have enough in common to conduct a meta-analysis. All statistics were two-sided, and a 
p<0.05 was considered statistically significant, except where otherwise stated. Microsoft 
Excel 2013 was used for the statistical analyses. 
DOI:10.14753/SE.2016.1921
 34 
 
3.2.3 Valuation of pemphigus health states by the general population 
3.2.3.1 Study overview 
A convenience sample of adults aged ≥18 years and able to understand the Hungarian 
language were recruited at the campus of Corvinus University of Budapest between 
December 2014 and May 2015. Data were collected using a paper-based questionnaire in 
group interviews. Participation in the study was voluntary, and respondents did not 
receive any compensation. Ethical approval was obtained from the Semmelweis 
University Regional and Institutional Committee of Science and Research Ethics 
(reference No. 275./2014). 
The groups consisted of up to 20 participants, and the average length of interview 
was 17 minutes. The interviews were led by two researchers (Fanni Rencz and 
Valentin Brodszky), both of whom had previous experience in leading TTO interviews. 
Subjects who decided to participate in the study were asked to fill in a self-completed 
questionnaire. However, during the interview process, respondents had the opportunity to 
ask the interviewer any question about the task. 
In the first section of the questionnaire, respondents were asked about their 
sociodemographic characteristics and whether they had any prior knowledge about 
pemphigus (e.g. had they ever heard about it, know someone with pemphigus, ever seen 
pemphigus patient(s) or been diagnosed with pemphigus?). Then, in the main part of the 
questionnaire, participants evaluated three hypothetical pemphigus health states by VAS 
and TTO. To help them understand the TTO task, we offered a warm-up question that 
involved a binocular blindness health state.  
3.2.3.2 Health state descriptions 
The results of our systematic review (Chapter 4.2.1), the items of a recently developed 
blistering skin disease-specific questionnaire, the Autoimmune Bullous Disease Quality 
of Life (ABQOL) [172] and consultations with two dermatologists were used to create 
three pemphigus health states: uncontrolled PV, uncontrolled PFo and controlled 
pemphigus. In the controlled state we did not distinguish between PV and PFo. The health 
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state vignettes were pilot-tested in four pemphigus patients at the Department of 
Dermatology, Venereology and Dermatooncology, Semmelweis University, in order to 
determine the clarity of descriptions and the TTO task.  
The health state vignettes provided a brief description of living with pemphigus, 
including experienced physical symptoms, possible food avoidance and issues about daily 
activities and social life from the second-person perspective (Table 3). The participants 
were asked to read the vignettes carefully and imagine being in the health state described. 
The order of the three health states within the questionnaire was as follows: uncontrolled 
PV, controlled pemphigus and uncontrolled PFo. 
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Table 3 Pemphigus health state descriptions 
 Uncontrolled pemphigus vulgaris Uncontrolled pemphigus foliaceus Controlled pemphigus 
Skin symptoms Blisters and erosions develop on 
approximately 25-30% (=25-30 palms) of 
your skin. The blisters are around 1-3 cm in 
diameter, very itchy and painful when 
appear. 
Bursting blisters may bleed and leave raw, 
red areas on your skin. After healing, your 
skin becomes pigmented. 
Erosions and scaling wounds develop 
on approximately 10-15% (=10-15 
palms) of your skin. The erosions are 
around 1-3 cm in diameter, moderate-
itchy and painful. 
Wounds typically heal slowly, and 
after healing your skin becomes 
pigmented. 
A few blisters or erosions can be 
seen on your skin and lips. The 
blisters are around 0.5-2 cm in 
diameter, a little itchy and rarely 
painful. 
Food avoidance There are erosions in your mouth and 
tongue, so you try to avoid hard (e.g. apple, 
fried steak, bread), spicy or acidic 
foods/drinks (e.g. tomato, orange, alcohol), 
which can cause sore and/or gingival 
bleeding. 
There are no erosions in your mouth, 
so you can eat and drink what you 
want. 
There are no erosions in your 
mouth, so you can eat and drink 
what you want. 
Bathing/clothing Showering/bathing and washing your hair 
can be very painful.  
You typically avoid any tight clothes and 
often wear gauze between your skin and 
clothes to prevent rubbing and bursting of 
the blisters. 
Showering/bathing and washing your 
hair can be very painful.  
You typically avoid any tight clothes 
and often wear gauze between your 
skin and clothes to prevent rubbing of 
the blisters. 
Showering/bathing and washing 
your hair can be a little 
bothersome. 
You can wear any clothes you 
want. 
Work Your skin condition leads to decreased 
productivity at the workplace and many sick 
days. 
Your skin condition leads to decreased 
productivity at the workplace and many 
sick days. 
Your skin condition does not affect 
your productivity at the workplace, 
you rarely miss work due to 
physician visits or treatments. 
Social life You feel embarrassed and anxious in the 
company of others due to your visible skin 
lesions. 
You feel embarrassed and anxious in 
the company of others due to your 
visible skin lesions. 
You only sometimes feel 
embarrassed and anxious in the 
company of others due to your 
visible skin lesions. 
DOI:10.14753/SE.2016.1921
 37 
 
3.2.3.3 Utility assessment 
We followed the checklist for utility assessment proposed by Stalmeier et al. [55]. In this 
study, two direct methods, VAS and TTO, were employed to value health states. The 
methodological background, as well as the use of these two measures in earlier 
dermatological research, is described in Chapter 1.3.2.1.  
Visual analogue scale 
Participants were asked to place each hypothetical health state on a horizontal 100-mm 
VAS ranging from 0 (worst possible health state) to 100 (best possible health state), which 
were then transformed to utilities (range 0-1). 
Time trade-off 
A new approach, the composite TTO, described by Janssen et al. [173] and applied in this 
study, is a combination of a conventional TTO for health states better than dead and a 
lead time TTO for states valued as worse than dead. This method proved feasibility and 
face-validity, and compared to the conventional TTO it led to a more consistent elicitation 
of negative values [173]. We decided to use a 10-year time frame, as this was used for 
the valuation of the EQ-5D health states in the Measurement and Valuation of Health 
study [174]. For worse than dead health states, a lead-time-to-disease time ratio of 1:1 
was applied. 
All valuations started with a conventional TTO as described by Gudex et al. [175]. 
The participants were instructed to choose between 10 years in a pemphigus health state 
versus a shorter life in perfect health. In order to conform to the self-completion 
methodology of our study, the iteration procedure was amended compared with that of 
Janssen et al. [173]. The top-down titration procedure was used by starting with 10 years 
in perfect health and descending to 0 years (10, 9.5, 9, 8, 7, etc.) (Figure 2) [175]. 
In the lead time TTO, respondents who preferred 0 years in perfect health (i.e. 
chose immediate death) over 10 years in a pemphigus health state were given 10 more 
years spent in perfect health before the 10 years to live in pemphigus (a total of 20 years). 
The alternative option offered ranged between 10 years and 0 years in perfect health 
(Figure 3). 
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Figure 2 Example for a conventional TTO self-completion sheet for health states 
better than dead 
 
Figure 3 Example for a lead time TTO self-completion sheet for health states worse 
than dead 
For the better than dead responses, utilities (U) were calculated by dividing the 
point of indifference between the two options by 10 years. For instance, if a respondent 
chose to live four years in perfect health over 10 years in a pemphigus health state, we 
get U = 8 / 10 = 0.8 (Figure 4). For worse than dead answers, if a participant has indicated 
that seven years in pemphigus is equal to 10 years in perfect health followed by 10 years 
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in pemphigus, the utility was estimated as U = (7-10)/10 = -0.3 (Figure 5). The range of 
TTO utilities in this study was -1 to 1, where U≤0 indicates states worse than dead. 
 
Figure 4 Calculation of utilities for health states better than dead 
Source: own figure based on Torrence et al. 1986, p.23 [51] 
 
 
Figure 5 Calculation of utilities for health states worse than dead 
Source: own figure based on Torrence et al. 1986, p.24 [51] 
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3.2.3.4 Statistical analysis 
In a sample size calculation, we estimated that in order to detect a difference of 0.10 with 
an assumed SD of 0.25 between TTO utilities with a two-sided α=0.05 and 80% power, 
we would need 64 observations per health state [106]. This was increased by 15% in order 
to enable using non-parametric statistics, as suggested in the literature [176]. Our sample 
size target was therefore at least 74 responses for each pemphigus health state. 
All non-missing TTO responses were included in the analyses. As a sensitivity 
analysis, we eliminated inconsistent responses and repeated all analyses. 
VAS and TTO utilities, and the differences in utilities between the three health 
states, were compared by employing a Wilcoxon signed-rank test. The impact of gender, 
level of education and employment status on utilities was assessed by a Mann-Whiney U 
test. Spearman’s rank order correlation was used to analyse the relationship between 
utilities and the participants’ age. All statistics were two-sided, and a p<0.05 was taken 
as statistically significant. Data analysis was carried out in SPSS 22.0 (Armonk, NY: IBM 
Corp. 2013). 
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3.3 DLQI study methods 
3.3.1 Design and setting 
A convenience sample of university students and staff was recruited at the campus of 
Corvinus University of Budapest, in order to participate in a cross-sectional survey. The 
questionnaire was administered through the Internet in March 2015. Inclusion criteria for 
the study included being able to understand Hungarian and aged 18 years or over. 
Individuals were invited to participate regardless of having any dermatological condition 
at the time of the survey. No remuneration was offered for completing the survey. The 
experiment was approved by the Semmelweis University Regional and Institutional 
Committee of Science and Research Ethics (reference No. 58./2015). 
The questionnaire consisted of three sections, each of which was displayed on a 
separate sheet. First, demographics (gender, age, level of education and employment) and 
data on any dermatological condition(s) diagnosed by a physician at the time of the survey 
were collected. On the second page, a warm-up TTO binocular blindness exercise was 
introduced to familiarise the respondents with health state valuations. Finally, each 
respondent valued three DLQI health states. The order of health states within the 
questionnaire was randomised for each subject. 
3.3.2 Health state descriptions 
The DLQI questionnaire is presented in detail in Chapter 1.3.2.4. We selected seven 
different DLQI health states: three of 11 points (labelled as L1-L3, where L is for large 
impact on HRQoL), three others of six points (M1-M3 where M refers to moderate impact 
on HRQoL) and one of 16 points (S, for the most severe health state) (Table 4). 
The 11-point health states were chosen, as Hongbo et al. described that a DLQI score 
greater than 10 indicates that the skin disease is having a very large impact on the patient’s 
life, and this is considered to be strong supportive evidence for the need for active patient 
intervention [130]. The difference between health states was set at 5 points, because this 
exceeds the minimal clinically important difference (MCID) for general inflammatory 
skin diseases (4 points) [3, 177].  
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Table 4 Seven DLQI health states 
Health state DLQI item scores 
Total DLQI 
score (0-30) 
Impact on quality of 
life* 
L1 3003020003 11 very large 
L2 2111111111 11 very large 
L3 1200300320 11 very large 
M1 3300000000 6 moderate 
M2 0001110111 6 moderate 
M3 2020002000 6 moderate 
S 3222212101 16 very large 
 * Hongbo, 2005 [130] 
In the names of health states, L refers to large impact on HRQoL, M refers to moderate impact on 
HRQoL and S is for the most severe health state. 
Only one health state of 16 points was selected, because we assumed this degree of 
HRQoL impairment as so severe that it was unlikely to result in significantly different 
utilities between health states of identical total scores. Amongst the 6- and 11-point states, 
we intended to compile as many different health state profiles as possible in terms of: 
 Affected items; 
 The total number of negatively affected items;  
 The severity level of impairment (i.e. the scoring of DLQI items from 0 to 3). 
Similarly to the ‘Pemphigus study’, a second-person point of view was applied in the 
description of health states. The descriptions contained neither labels nor names of any 
specific dermatologic conditions. We made no changes to the original 10 items of the 
DLQI (including the bold font words) with the exception of the order of the questions. To 
make any differences between health states easily perceivable, we rearranged the 10 
items, which were classified into two to four blocks based on the severity level of 
impairment (Figure 6). Thus, items with ‘very much’ impairment or ‘prevented work or 
studying’ moved to the top, followed by items affected ‘a lot’, ‘a little’ and finally ‘not at 
all’. In the original questionnaire, eight DLQI items also had ‘not relevant’ options, which 
were scored, as they were ‘not at all’ answers. In this study, we did not add any ‘not 
relevant’ responses to the health state descriptions. 
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Figure 6 DLQI health state description example: ‘L3’ 
 
3.3.3 Time trade-off 
The study was carried out in accordance with the checklist for utility assessment proposed 
by Stalmeier et al. [55]. We opted to perform the utility assessment in a general population 
sample because of the following reasons: 
i) We intended to avoid biases on selecting a patient population with a particular 
diagnosis; 
ii) Utilities from the general population are recommended to be used for 
reimbursement decisions in healthcare in many jurisdictions, including Hungary 
[9, 89-91]; 
iii) A series of outcome measures can be found in other fields of medicine, for which 
utilities were derived from a general population sample, e.g. Asthma Quality of 
Life Questionnaire, Overactive Bladder Questionnaire, Short Bowel Syndrome 
health-related quality of life scale, Myelofibrosis-Symptom Assessment Form, 
European Organisation for Research and Treatment of Cancer Quality of Life 30 
Questionnaire [178-180].  
Affects you very much: 
Your skin affects your social or leisure activities very much. 
 Your skin creates very much problems with your partner or some of your 
close friends or relatives. 
Affects you a lot: 
You are embarrassed or self-conscious a lot because of your skin. 
 Your skin causes a lot sexual difficulties. 
Affects you a little: 
Your skin is a little itchy, sore, painful or stinging.  
Does not affect you at all: 
Your skin does not interfere with you at all going shopping or looking 
after your home or garden. 
Your skin does not influence at all the clothes you wear. 
Your skin does not make it difficult at all to do sports. 
Your skin is not a problem at all at work or studying. 
Treatment of your skin, for example by making your home messy, or by 
taking up time, is not a problem at all.  
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The TTO task was identical to the utility assessment for better than dead health 
states in the ‘Pemphigus study’ (Chapter 3.2.3.3). Missing or inconsistent TTO responses 
were excluded from the analysis. Respondents who were unable to provide a valid answer 
within any TTO task were excluded from the whole study. 
3.3.4 Statistical analysis 
A sample size calculation was performed. We estimated that in order to detect an expected 
difference of 0.10 with an assumed SD of 0.25 between utilities [106], 100 valid responses 
would be necessary per health state to achieve a power of 80% and α=0.05 (running a 
two-tailed test). However, the distribution of health utilities is typically skewed because 
of being bounded by the limits of the scale (here: 0, 1) [181]. Thus, we increased the 
estimated sample size by 15% to enable using non-parametric tests [176]. We aimed to 
reach 115 observations per health state.  
Descriptive statistics were performed to examine demographics. A Mann-
Whitney U test was applied to compare utilities for different health states and the 
respondents’ answers, with or without any dermatological condition. In a sensitivity 
analysis, we eliminated all responses from respondents with any dermatological condition 
and repeated all analyses. All statistics were two-tailed at the 0.05 significance level. Data 
were analysed using SPSS 22.0 (Armonk, NY: IBM Corp. 2013).   
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4 Results 
4.1 Psoriasis study 
4.1.1 Patient characteristics 
A total of 200 patients with moderate-to-severe psoriasis participated in the survey. 
Sociodemographic and clinical characteristics of the patients are described in Table 5. The 
mean age was 51 years (range 21-85 years), and 69% were male. Almost 80% were 
overweight (body mass index, BMI≥25). Two-thirds of the patients were married or 
cohabiting. The majority had completed secondary education (79%), and one-fifth 
reported to have a college or a university degree. Despite 174 (87%) patients being of 
working age, only 100 (50%) were employed. Overall, 21% were disabled pensioners, 
19% were retired, 4% were unemployed and 2% were students. Net monthly income in 
78% of the patients was equal to or less than HUF 150,000 (EUR 526)2. 
The mean disease duration was 22 years. Seventy-two (36%) patients reported a 
family history of psoriasis. The following clinical subtypes occurred in the sample: 
chronic plaque psoriasis (63%), nail psoriasis (36%), scalp psoriasis (35%), psoriatic 
arthritis (29%), inverse psoriasis (9%), palmoplantar psoriasis (6%), erythrodermic 
psoriasis (2%) and guttate psoriasis (2%) (combinations are possible). 
Out of the 200 patients, 30% had been hospitalised at least once due to psoriasis 
in the last 12 months, and 80% had made at least one visit to a dermatologist in the last 
three months. Few patients (14%) used professional or informal home help. At the time 
of the survey, 103 (52%) received biological drug in mono- or combination therapy, 61 
(31%) systemic non-biological therapy, 30 (15%) only topical treatment and six (3%) 
were untreated. Methotrexate (17%) and retinoids (7%) were the most commonly applied 
systemic non-biological therapies, whereas infliximab (19%) and adalimumab (17%) 
were the most frequent biological agents used. Eighteen patients (9%) were about to start 
their first biological drug (Table 5). 
  
                                                 
2 EUR 1 = HUF 285 (year 2014) 
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Table 5 Socio-demographic and clinical characteristics of the psoriasis patient 
population 
Total (N=200) 
Mean (SD)   Number of patients (%)   
Age (years) 51.2 (12.9) Clinical subtypes**  
Psoriasis duration (years) 22.0 (11.7) Chronic plaque psoriasis 126 (63%) 
Body mass index (BMI) 
(kg/m2)  
29.9 (5.5) Erythrodermic psoriasis 
4 (2%) 
EQ-5D index (-0.594-1) 0.69 (0.31) Guttate psoriasis  4 (2%) 
EQ VAS (0-100) 64.43 (21.34) Inverse psoriasis 18 (9%) 
DLQI (0-30) 6.29 (7.29) Nail psoriasis 71 (36%) 
PASI (0-72) 8.01 (10.01) Scalp psoriasis 69 (35%) 
Number of patients (%)  Psoriatic arthritis 57 (29%) 
Gender (male) 137 (69%) Palmoplantar psoriasis 12 (6%) 
Positive family history 
(missing n=1) 
72 (36%) Number of present clinical subtypes 
 
Married/cohabiting 
(missing n=1) 
131 (66%) 
0 (asymptomatic at the time of the 
survey) 
57 (29%) 
Education  1 33 (16%) 
Primary school 43 (22%) 2-3 83 (42%) 
Secondary school 117 (59%) ≥4 27 (14%) 
College/university 40 (20%) Health services  
Employment (missing n=4) 
 
Visit(s) to general practitioner (last one 
month) * 
49 (25%) 
Full-time 
79 (40%) 
Visit(s) to dermatologist (last three 
months)* 
159 (80%) 
Part-time 21 (11%) Hospitalisation (last 12 months)* 59 (30%) 
Unemployed 
7 (4%) 
Use of professional or informal home 
help (last one month) 
27 (14%) 
Disabled pensioner* 41 (21%) Present treatment  
Retired 38 (19%) Not treated 6 (3%) 
Student  2 (1%) Topical treatments 30 (25%) 
Other 8 (4%) Systemic non-biological treatments 61 (32%) 
Net monthly income (HUF) 
(missing n=10) 
 Methotrexate 
35 (17%) 
< 75,000 78 (39%) Cyclosporine 7 (4%) 
75,001-150,000 78 (39%) Phototherapy 5 (3%) 
150,001-250,000 21 (11%) Retinoid 14 (7%) 
250,001-350,000 7 (4%) Biological treatment 103 (52%) 
> 350,000 6 (4%) Adalimumab 33 (17%) 
 
Etanercept 16 (8%) 
Infliximab 38 (19%) 
Ustekinumab 16 (8%) 
First biological is indicated at the time 
of the survey 
18 (9%) 
* Due to psoriasis. ** Combinations may occur.  
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4.1.2 Health status and HRQoL in psoriasis patients 
Psoriasis patients’ mean EQ-5D, EQ VAS, DLQI and PASI scores were 0.69±0.31, 64.43 
±21.34, 6.29±7.29 and 8.01±10.01, respectively. Overall, 51 patients (25%) marked the 
best possible health state in EQ-5D (11111). Ten patients (5%) rated their health status as 
being worse than dead (i.e. negative EQ-5D scores). Most patients reported problems in 
the pain/discomfort domain of the EQ-5D descriptive system (60%), followed by mobility 
(47%), anxiety/depression (47%), usual activities (39%) and self-care (14%) (Figure 7). 
The highest rates of patients indicating extreme problems were noted in the 
pain/discomfort (9%) and anxiety/depression domains (7%).  
4.1.3 Comparison of health status of patients and the general population 
General health status of psoriasis patients measured by EQ-5D dimension percentages 
was found to be worse compared to the age-matched general population in Hungary 
(Figure 7). 
 
 
Figure 7 Comparison of EQ-5D dimensions between moderate-to-severe psoriasis 
patients and the general population 
General population norm: Szende-Németh 2003 [118] 
DOI:10.14753/SE.2016.1921
 48 
 
Similarly, we found EQ-5D index scores in patients of both females and males with 
psoriasis lower compared to the general population (Figure 8). The difference was 
significant for the age groups 18-24, 25-34, 45-54 and 55-64 in males, and 35-44, 45-54 
and 55-64 in females (p<0.05). 
 
Figure 8 Comparison of mean EQ-5D index scores between moderate-to-severe 
psoriasis patients and the general population by age group 
General population norm: Szende-Németh 2003 [118] 
* significant difference (p<0.05) 
4.1.4 HRQoL and disease severity in patient subgroups  
The comparison of EQ-5D, EQ VAS, DLQI and PASI scores between patient subgroups 
is presented in Table 6. Despite the lack of significant difference in PASI scores between 
the two genders, female patients showed lower EQ-5D scores compared to males (0.62 
vs. 0.73, p<0.001). No significant difference was identified between genders in EQ VAS 
(62.9 and 65.1, p=0.461) or DLQI (7.20 and 5.88, p=0.535). Both EQ-5D and EQ VAS 
demonstrated a significant correlation with age (rs=-0.20, p=0.004 and rs=-0.24, p=0.001). 
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Among clinical subtypes, patients with palmoplantar psoriasis and psoriatic 
arthritis reported the worst health status (mean EQ-5D 0.36 and 0.48, EQ VAS 50.33 and 
56.61, DLQI 11.42 and 9.26). The use of health services such as visits to a GP, 
hospitalisation and the necessity of home help were significant determinants of decreased 
HRQoL. Visits to dermatologist(s) in the last three months had no impact on HRQoL 
outcomes. Patients that used home help in the last month experienced particularly 
impaired HRQoL (mean EQ-5D 0.35). Patients treated with biologicals rated their 
HRQoL significantly better compared to those on either systemic non-biological, topical 
or no treatment (mean EQ-5D 0.75 vs. 0.63, EQ VAS 70.72 vs. 57.46 and DLQI 2.14 vs. 
10.80, p<0.001 for all). 
4.1.5 Subjective expectations on HRQoL for six months ahead 
Out of the 200 patients who participated in the survey, answers of 167 were included in 
the analysis of expectations. Psoriasis patients expected to improve on average by 
0.10±0.23 for their EQ-5D score within six months (p<0.001) (Table 7). Overall, 83 
(49%) expected no change at all in any of the five dimensions of EQ-5D. Sixty-two (37%) 
and 22 (13%) patients expected increases and decreases in HRQoL, respectively. The 
mean EQ-5D score of those who expected better, same or worse HRQoL in six months 
were 0.52, 0.86 and 0.69, respectively (p<0.001). Those who expected amelioration 
expected more than a two-fold increase in the EQ-5D score (0.32) compared with those 
who expected a deterioration (-0.12). The most prominent improvement was expected in 
the dimensions of anxiety/depression and pain/discomfort (16% and 17% expected to 
reach the level of ‘no problems’, respectively). 
Female gender, younger age, non-marital status, psoriatic arthritis, palmoplantar 
or inverse psoriasis, worse health state (measured by EQ-5D, DLQI or PASI), being at 
the initiation of first biological therapy or being treated by topical therapy were associated 
more often with optimistic expectations. On the contrary, older patients, those in a better 
health state (EQ-5D) and those with nail or scalp involvement tended to expect 
deterioration. The difference between actual and expected EQ-5D demonstrated a 
moderate inverse correlation with the actual EQ-5D and EQ VAS and a weak positive 
correlation with DLQI and PASI. The more severe the patients’ current health state, the 
higher their expectations (Table 8).  
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Table 6 Differences in HRQoL and disease severity between subgroups 
 EQ-5D EQ VAS DLQI PASI 
 N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
Gender         
Male 132 0.73 (0.31)* 135 65.10 (21.15) 134 5.88 (6.91) 137 8.14 (10.22) 
Female 60 0.62 (0.31)* 61 62.94 (21.86) 60 7.20 (8.06) 63 7.72 (9.63) 
Clinical subtypes         
Chronic plaque psoriasis 123 0.63 (0.32)* 126 60.17 (20.55)* 125 8.84 (7.23)* 126 11.70 (10.27)* 
Erythrodermic psoriasis 4 0.71 (0.33) 4 62.25 (15.28) 4 10.25 (8.81) 4 20.40 (10.71)* 
Guttate psoriasis  4 0.74 (0.08) 4 48.00 (10.16) 4 7.25 (5.06) 4 16.03 (7.89)* 
Inverse psoriasis 17 0.55 (0.40) 17 54.12 (22.81)* 17 13.12 (6.37)* 18 21.83 (14.92)* 
Nail psoriasis 68 0.62 (0.32)* 71 58.96 (20.22)* 71 10.00 (7.28)* 71 13.47 (10.55)* 
Palmoplantar psoriasis 12 0.36 (0.39)* 12 50.33 (21.42)* 12 11.42 (6.82)* 12 18.38 (16.04)* 
Psoriatic arthritis 56 0.48 (0.36)* 57 56.61 (20.76)* 57 9.26 (7.70)* 57 12.42 (11.47)* 
Scalp psoriasis 67 0.62 (0.31)* 69 56.95 (19.55)* 69 12.42 (6.55)* 69 16.19 (10.71)* 
Health services         
GP visit(s) in the last month** 47 0.47 (0.32)* 48 51.99 (20.58)* 48 11.21 (7.76)* 49 12.59 (10.74)* 
Dermatologist visit(s) in the last three months 152 0.67 (0.32) 156 63.11 (21.19) 156 6.22 (7.48) 159 7.74 (10.07) 
Hospitalisation(s) in the last 12 months ** 54 0.59 (0.36)* 56 53.44 (21.91)* 56 10.05 (8.08)* 57 11.61 (9.64)* 
Use of home help in the last month 27 0.35 (0.41)* 27 52.65 (21.43)* 27 13.70 (6.70)* 27 17.77 (12.40)* 
Treatments         
No or topical therapy 32 0.65 (0.31) 32 54.50 (20.44) 32 12.22 (6.45) 36 18.43 (11.16) 
Systemic non-biological therapy 58 0.62 (0.31) 61 59.01 (17.12) 61 10.05 (7.80) 61 11.19 (9.55) 
Biological therapy 102 0.75 (0.31)* 103 70.72 (21.96)* 101 2.14 (3.92)* 103 2.50 (4.91)* 
* Mann-Whitney U test or Kruskal-Wallis test p<0.05; ** due to psoriasis. 
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Table 7 HRQoL expectations for six months ahead and future ages of 60 to 90 
 
N (%) 
Actual EQ-
5D 
Expected EQ-5D 
score for six 
months ahead 
Difference between 
actual score and six 
months expectations 
Expected EQ-5D scores for future ages 
60 70 80 90 
N (response rate, %) 167 (100%) 114 (93%) 143 (88%) 119 (72%) 92 (55%) 
Total sample 167 0.71 (0.30) 0.81 (0.24) 0.10 (0.23)a 0.56 (0.48) 0.38 (0.50) 0.15 (0.55) -0.17 (0.54) 
Gender         
Female 49 (29%) 0.62 (0.32) 0.80 (0.25) 0.18 (0.28) a,b 0.31 (0.60) b 0.27 (0.56) 0.06 (0.57) -0.20 (0.56) 
Male 118 (71%) 0.75 (0.28) 0.82 (0.24) 0.07 (0.20) a,b 0.66 (0.38) b 0.43 (0.46) 0.20 (0.54) -0.16 (0.53) 
Clinical subtypes §, **         
Chronic plaque psoriasis 107 (64%) 0.65 (0.30) 0.77 (0.26) 0.13 (0.25) a 0.48 (0.51) b 0.29 (0.53) b 0.07 (0.56) b -0.26 (0.52) b 
Inverse psoriasis 15 (9%) 0.61 (0.33) 0.89 (0.18) 0.28 (0.33) a,b 0.63 (0.43) 0.42 (0.62) 0.20 (0.58) -0.11 (0.61) 
Nail psoriasis 59 (35%) 0.63 (0.31) 0.76 (0.26) 0.13 (0.23) a 0.42 (0.53) b 0.25 (0.56) b 0.03 (0.59) -0.21 (0.55) 
Scalp psoriasis 59 (35%) 0.64 (0.29) 0.75 (0.29) 0.10 (0.21) a 0.45 (0.54) 0.21 (0.59) b -0.01 (0.58) b -0.20 (0.61) 
Psoriatic arthritis 48 (29%) 0.51 (0.34) 0.70 (0.31) 0.19 (0.29) a,b 0.30 (0.57) b 0.16 (0.55) b 0.04 (0.55) -0.17 (0.57) 
Palmoplantar psoriasis 9 (5%) 0.48 (0.31) 0.75 (0.20) 0.27 (0.22) b 0.57 (0.36) 0.44 (0.33) 0.42 (0.29) -0.04 (0.78) 
Number of present clinical 
subtypes 
        
0 (asymptomatic at the time of 
the survey) 
47 (28%) 0.87 (0.23) 0.92 (0.14) 0.05 (0.18) 0.76 (0.31)b 0.58 (0.34) b 0.33 (0.50) b -0.02 (0.54) 
1 28 (17%) 0.71 (0.26) 0.79 (0.22) 0.08 (0.25) 0.53 (0.50) b 0.37 (0.47) b 0.05 (0.52) b -0.33 (0.42) 
2-3 70 (42%) 0.67 (0.29) 0.80 (0.23) 0.13 (0.23) a 0.54 (0.47) b 0.36 (0.51) b 0.18 (0.55) b -0.20 (0.55) 
≥4 22 (33%) 0.49 (0.33) 0.66 (0.36) 0.17 (0.28) a 0.16 (0.59) b 0.03 (0.59) b -0.13 (0.58) b -0.24 (0.60) 
Present treatment***         
Topical  17 (10%) 0.64 (0.34) 0.91 (0.16) 0.26 (0.33) a 0.91 (0.18) b 0.53 (0.48) 0.31 (0.56) 0.21 (0.66) 
Systemic non-biological 40 (24%) 0.65 (0.29) 0.72 (0.23) 0.07 (0.19) a 0.40 (0.50) b 0.23 (0.53) -0.04 (0.51) -0.28 (0.55) 
Biological 94 (56%) 0.76 (0.28) 0.84 (0.22) 0.08 (0.21) a 0.58 (0.47) b 0.41 (0.49) 0.22 (0.54) -0.13 (0.51) 
First biological is indicated at 
the time of the survey 
14 (8%) 0.59 (0.34) 0.77 (0.37) 0.18 (0.27) a 0.47 (0.55) b 0.29 (0.49) -0.02 (0.64) -0.41 (0.45) 
Expected survivors* (N, % of 
respondents) 
- - - - 
109 (96%) 130 (90%) 62 (52%) 18 (20%) 
Expected survivors - - - - 0.59 (0.46) a 0.48 (0.41) a 0.42 (0.41) a 0.22 (0.47) a 
Expected non-survivors - - - - -0.32 (0.32) a -0.06 (0.61) a -0.14 (0.53) a  -0.26 (0.51) a 
a: Wilcoxon signed-rank test p<0.05; b: Mann-Whitney U test or Kruskal Wallis test p<0.05. § Combinations are possible. * Expected to live until the future age asked. 
** Two patients had guttate or erythrodermic psoriasis. *** Two patients had received no therapy at the time of the survey.
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Table 8 Correlations between expectations and continuous variables 
 
Expected EQ-5D in six 
months 
Expected length of life Expected EQ-5D at the age of … 
 
EQ-5D in six 
months 
Difference 
[expected in 
six months – 
actual EQ-5D] 
Subjective 
LE 
Difference 
[subjective 
– actual LE] 
60 yrs 70 yrs 80 yrs 90 yrs 
Age -0.34* -0.11 0.21* -0.07 -0.20* -0.02 0.09 0.03 
Subjective 
LE 
0.30* -0.11 - 0.90* 0.43* 0.50* 0.55* 0.48* 
Actual LE -0.27* 0.03 0.14 -0.26* 0.33* -0.12 -0.03 -0.04 
Psoriasis 
duration 
-0.31* -0.09 0.06 -0.03 -0.29* -0.11 -0.05 -0.04 
EQ-5D 0.66* -0.44* 0.35* 0.47* 0.62* 0.57* 0.52* 0.52* 
EQ VAS 0.51* -0.06 0.29* 0.36* 0.52* 0.43* 0.43* 0.38* 
DLQI -0.24* 0.18* -0.20* -0.20* -0.16 -0.25* -0.21* -0.26* 
PASI -0.22* 0.18* -0.12* -0.14 -0.21* -0.22* -0.14 -0.20 
* Spearman’s correlation p<0.05. For EQ-5D and EQ VAS a higher score, for DLQI and PASI a lower score 
refers to a better health state.  
4.1.6 Subjective expectations for life expectancy 
The results related to subjective LE are presented in Table 9. Male and female patients 
expected to live until 74.86±9.54 and 80.09±1.77 years, respectively. For males we found an 
overestimation, while for females we uncovered an underestimation of the gender- and age-
matched statistical LE. Palmoplantar involvement, inverse psoriasis, psoriatic arthritis and 
scalp psoriasis were responsible for the largest underestimations (-4.01, -3.01, -2.67, -1.65 
years). Patients presenting four or more clinical subtypes, and those at the initiation of their 
first biological treatment, had very low expectations. Patients’ age, EQ-5D, EQ VAS, DLQI 
and PASI scores correlated moderately or weakly with subjective LE (Table 8). 
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Table 9 Difference between actual and expected life expectancy  
a: Wilcoxon signed-rank test p<0.05; b: Mann-Whitney U or Kruskal-Wallis test p<0.05.*Combinations are 
possible. ** Two patients had guttate or erythrodermic psoriasis. § Two patients had received no therapy at the 
time of the survey. 
  
  
 N (%) Subjective LE Actual LE 
Difference 
subjective-
actual LE 
 167 76.21 (10.92) 75.82 (4.05) 0.39 (11.21) 
Gender     
Female 49 (29%) 74.86 (9.54) 80.09 (1.77) -5.23 (9.34) a,b 
Male 118 (71%) 76.77 (11.43) 74.04 (3.34) 2.73 (11.14) a,b 
Education     
Lower 32 (19%) 73.50 (13.50) 76.82 (3.69) -3.32 (12.62) 
Secondary 98 (59%) 75.57 (9.61) 75.50 (4.23) 0.07 (9.91) 
College/university 37 (22%) 80.24 (11.29) 75.79 (3.82) 4.46 (11.25) a 
Net monthly income (HUF)     
< 75,000 62 (37%) 75.29 (12.08) 76.44 (3.81) -1.15 (12.52) b 
75,001-150,000 65 (39%) 75.62 (9.66) 75.65 (4.25) -0.03 (9.22) b 
150,001-250,000 21 (13%) 79.00 (8.55) 75.64 (4.26) 3.36 (9.41) b 
250,001-350,000 11 (7%) 84.09 (8.79) 74.58 (3.51) 9.51 (8.46) a,b 
Clinical subtypes*     
Chronic plaque psoriasis 107 (64%) 75.75 (10.82) 75.89 (4.08) -0.14 (11.15) 
Inverse psoriasis 15 (9%) 74.53 (10.19) 77.55 (4.38) -3.01 (8.69) 
Nail psoriasis 59 (35%) 73.93 (11.18) 75.52 (3.86) -1.59 (11.09) 
Scalp psoriasis 59 (35%) 74.71 (11.34) 76.36 (4.29) -1.65 (11.57) b 
Psoriatic arthritis 48 (29%) 74.06 (10.32) 76.73 (3.60) -2.67 (10.32) 
Palmoplantar psoriasis 9 (5%) 73.89 (8.85) 77.90 (3.36) -4.01 (8.44) 
Number of present clinical 
subtypes 
    
0 (asymptomatic at the time of 
the survey) 
47 (28%) 77.49 (11.61) 75.40 (4.15) 2.09 (11.99) 
1 28 (17%) 78.43 (10.29) 76.11 (3.65) 2.32 (10.93) 
2-3 70 (42%) 75.89 (10.32) 75.36 (4.16) 0.53 (10.42) 
≥4 22 (33%) 71.68 (11.35) 77.80 (3.55) -6.12 (10.65)a 
Present treatment§     
Topical 17 (10%) 76.76 (8.02) 76.16 (4.28) 0.61 (7.41) 
Systemic non-biological 40 (24%) 76.55 (11.25) 76.17 (4.22) 0.38 (12.14) 
Biological 94 (56%) 76.51 (12.61) 75.36 (4.00) 1.15 (12.92) 
Initiation of first biological at the 
time of the survey 
14 (8%) 73.43 (7.06) 76.88 (3.65) -3.45 (6.20)a 
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4.1.7 Expectations for HRQoL at future ages 
The age range of respondents answering questions concerning HRQoL expectations for older 
ages was roughly relevant to the sample, because 73%, 97%, 99% and 100% of the patients 
were below the ages asked (60-90), respectively (Table 7). Expected survivors rated their 
future EQ-5D at ages of 60 to 90: 0.59±0.46, 0.48±0.41, 0.42±0.41 and 0.22±0.47. While 
survivors scored positive EQ-5D scores at each given age, non-survivors scored on average 
negative, even for the age of 60. This finding is confirmed by the significant moderate 
correlation found between subjective LE and expected future EQ-5D scores (Figure 8). For 
each decade, the highest decline was expected in mobility and pain/discomfort dimensions 
of EQ-5D.  
Males expected to have a better HRQoL at each future age, but this was only 
significant for the age of 60 (p=0.005). Future HRQoL expectations correlated moderately 
with current EQ-5D and EQ VAS. A weak inverse correlation was identified between future 
HRQoL and either DLQI or PASI (Figure 8).  
4.1.8 Comparison of HRQoL expectations with the general population 
HRQoL expectations for future decades were compared to findings from the age-matched 
participants of a similar study of the Hungarian general population (Figure 9) [165]. The 
expectations of psoriasis patients are considerably lower than those of the general population 
in Hungary. However, for the age of 70, actual EQ-5D values of the age-matched patients 
within the sample substantially exceeded expectations (0.73 vs. 0.38). 
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Figure 9 Comparison of subjective HRQoL expectations in EQ-5D for older ages 
between psoriasis patients and the general population 
General population and psoriasis patients between the ages of 55-64, 65-74, 75-84 and 85-94 represent the age 
categories of 60, 70, 80 and 90, respectively. The results for psoriasis patients aged 75 or more are not depicted 
here, as there was only one patient over the age of 75. 
Data sources: Péntek et al. 2012 [165], Szende-Németh 2003 [118] 
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4.2 Pemphigus study 
4.2.1 Systematic review 
4.2.1.1 Characteristics of included studies 
The search strategy identified 612 records. Appendix 12.3 presents the PRISMA flowchart 
used in the selection process [182]. After removing duplicates, 368 records were screened on 
title and abstract. Out of the 35 papers remaining for full-text review, 21 were excluded based 
on predefined exclusion criteria. Screening references yielded two more papers that were not 
indexed in electronic databases but met the inclusion and exclusion criteria. Thus, in total, 
16 studies were included in the systematic review.  
The main findings of the 16 papers are summarised in Table 10 [183-198]. Studies 
originated from eight different countries: Italy (n=5) [190, 191, 193-195], Iran (n=4) [183-
185, 187], India (n=2) [186, 192], Japan (n=1) [188], Germany (n=1) [189], Poland (n=1) 
[198], Morocco (n=1) [196] and Brazil (n=1) [197].  
There were 11 cross-sectional studies [183, 185-190, 192-195], four case-control studies 
[189, 191, 196, 198] and one prospective cohort with a four-month follow-up period [197]. 
The patient populations varied between seven and 380 patients, with only five studies 
enrolling >100 participants [183, 188, 190, 191, 195]. The 16 studies involved a total of 1,465 
patients, of whom 966 (66%) had PV. Besides PV, the following types of pemphigus 
occurred: 123 PFo, 41 seborrheic, eight vegetans, two IgA and two paraneoplastic. The 
clinical type of 323 (22%) patients was unknown or not specified. The mean age of the 
included patients ranged between 39.3 and 61.6 years (n=12) [183, 185, 187-192, 195-198], 
and the rate of males varied from 37% to 80% (n=13) [183-192, 195, 196]. 
Two studies recruited only newly diagnosed or untreated patients [183, 185], five 
enrolled patients on adjuvant and/or corticosteroid therapy [184, 186, 190, 191, 196] and a 
small study investigated the impact of physiotherapy on HRQoL [197].  
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4.2.1.2 HRQoL measures used in pemphigus 
Four types of HRQoL instruments were used: Short form-36 (SF-36), Activities of Daily 
Livings (ADLs), World Health Organization Quality of Life-BREF (WHOQOL-BREF), and 
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Four 
different dermatology- or oral disease-specific measures were applied: Dermatology Life 
Quality Index (DLQI), Skindex-29, Skindex-17, and Chronic Oral Mucosal Diseases 
Questionnaire (COMDQ). Among these, SF-36 (n=8), DLQI (n=5) and Skindex-29 (n=4) 
were the most frequent. 
Furthermore, half of the studies applied at least one psychological/psychiatric 
measure, the most common of which was the General Health Questionnaire (GHQ)-12 or -
28 (n=7) [183, 185, 186, 190, 191, 193, 195].
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Table 10 Pemphigus HRQoL studies identified 
Author,  
year 
Country, 
study 
period 
Study type Patients’ characteristics 
HRQoL 
measures 
HRQoL scores (mean) 
Determinants of 
decreased HRQoL 
Sakuma, 
2000[188] 
Japan 
Sep.-Dec. 
1997 
 
cross-
sectional 
n=380 (PV 239, foliaceus 
80, seborrheic 31, 
vegetans 6, other 6, 
unknown 18), 78.7% in 
remission, 69% treated 
for > 2 years 
Males: 39% 
Mean age: males 58.1, 
females 52.5 years 
ADLs 
Rate of patients: bathe alone 
96.5%; use the toilet alone 
99.7%; eat alone 99.7%; pain 
while eating or swallowing 
40.4%; cook alone 85.2%; 
shave or make-up alone 97.0%; 
use public transport alone 
90.8%; drive a car 82.3% 
- 
Terrab, 
2005[196] 
Morocco 
Jan.-Aug. 
2002 
case-
control 
n=30 (PV 14, seborrheic 
10, foliaceus 4, vegetans 
2), 70% corticosteroid, 
30% adjuvant 
(+corticosteroid) 
treatment 
Males: 20% 
Mean age: 44.6 years 
SF-36 
PF 59.5; RP 10.0; BP 57.0; GH 
48.6; VT 35.5; SF 43.7; RE 
8.8; MH 40.4 
Profession,  
Face involvement 
Extent of lesions 
Mayrshofer, 
2005[189]  
Germany 
Nov. 1997-
Jan. 2002 
cross-
sectional 
n=27 PV, newly 
diagnosed 
Males: 40% 
Mean age: 55.9 years 
DLQI 
10.0±6.7, symptoms 1.4; self-
confidence 1.6; shopping and 
housekeeping 1.0; clothing 0.9; 
leisure 1.3; sport 0.6; work and 
school 0.9; relationships 1.0; 
sexuality 0.6; treatment 1.0.  
- 
Tabolli, 
2006[193] 
Italy 
Feb.-May 
2005 
cross-
sectional 
n=13 (type not specified) 
Males: NR 
Mean age: NR 
SF-36 
PF 57.7; RP 34.1; BP 55.8; GH 
51.0; VT 55.0; SF 52.9; RE 
60.6; MH 50.8 - 
Skindex-29 
symptoms 47.3; emotions 46.7; 
social functioning 40.5 
Tabolli, 
2008[194] 
Italy 
Jan.-June 
2006 
cross-
sectional 
n=58 (PV 51, foliaceus 
7),  
75% in-patients 
Males: 43% 
Mean age: NR 
SF-36 
P. vulgaris: PF 72; RP 43; BP 
63; GH 49; VT 49; SF 61; RE 
47; MH 53 
PGA >4  
Disease duration ≥ 5 years 
ASQ or CDQ≥8 
Mucocutaneus lesions 
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Author,  
year 
Country, 
study 
period 
Study type Patients’ characteristics 
HRQoL 
measures 
HRQoL scores (mean) 
Determinants of 
decreased HRQoL 
P. foliaceus: PF 79; RP 46; BP 
66; GH 48; VT 63; SF 65; RE 
62; MH 61 
Darjani, 
2008[184] 
Iran 
April –July 
2005 
case-
control 
n=76 (type not specified), 
corticosteroid or adjuvant 
(+corticosteroid) 
treatment 
Males: 42.3% 
Mean age: 31.6% 40-49 
years 
SF-36 
PF 71.9; BP 74.0; RP 55.8; RE 
69.9; VT 59.0; GH 59.0; SF 
90.1; MH 69.4 
Older age 
Longer disease duration  
Lower education level 
Job 
Repeated hospitalisations 
Treatment with adjuvant 
(+corticosteroid) 
Paradisi, 
2009[191] 
Italy 
Feb. 2007-
Feb. 2008 
case-
control 
n=126 (PV 112, foliaceus 
10, paraneoplastic 2, IgA 
pemphigus 2), 
corticosteroid and/or 
adjuvant therapy 
Males: 53% 
Mean age: 52.2 years 
SF-36 
P. vulgaris: PF 73; RP 45; BP 
61; GH 49; VT 53; SF 62; RE 
49; MH 56; PCS 43; MCS 37. 
P. foliaceus: PF 65; RP 47; BP 
56; GH 47; VT 46; SF 57; RE 
60; MH 56, PCS 39; MCS 38. 
Age > 50 
Female 
PGA >1 
Ikeda >3 
Comorbidities≥2** 
Treatment with ≤10 
mg/day corticosteroids 
Skindex-29 
P. vulgaris: symptoms 36; 
emotions 36; social functioning 
32 
P. foliaceus: symptoms 52; 
emotions 46; social functioning 
52 
Female 
PGA >1 
Ikeda >3 
PV 
Timoteo, 
2010[197] 
Brazil 
NR 
prospective 
cohort  
(4-month 
follow up) 
n=7 (type not specified), 
treated with 
physiotherapy 
Males: 80% of the total 
sample (n=15) 
Mean age: 40 years 
(n=15) 
SF-36 
Physiotherapy improved 
HRQoL after 4 months in all 
dimensions of SF-36 except for 
VT and SF 
(results reported graphically) 
Physiotherapy 
Arbabi, 
2011[183] 
Iran 
Apr. 2004- 
June 2008 
cross-
sectional 
n=212, (PV 206, 
foliaceus 6), 56% newly 
diagnosed 
Males: 42% 
Mean age: 44.9 years 
DLQI 
 
Total: 13.8, new patients 12.8, 
patients with recurrent attack 
15.9 
GHQ-28 
Recurrence of pemphigus 
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Author,  
year 
Country, 
study 
period 
Study type Patients’ characteristics 
HRQoL 
measures 
HRQoL scores (mean) 
Determinants of 
decreased HRQoL 
Paradisi, 
2012[190] 
Italy 
Feb. 2007- 
Feb. 2009 
cross-
sectional 
n=113 (PV 103, foliaceus 
10), 70% traditional 
adjuvant, 20% rituximab 
Males: 37% 
Mean age: 50 years 
SF-36 
PCS 42.8; MCS: 37.8 GHQ-12 
Not receiving adjuvant 
therapy  
Skindex-29 
symptoms 33.9; emotions 34.8; 
social functioning 31.7 
GHQ-12 
Ghodsi, 
2012[185] 
Iran 
July 2005-
June 2006 
cross-
sectional 
n=61 PV, newly 
diagnosed 
Males: 38%  
Mean age: 44.1 years* 
DLQI 
 
Total: 10.9 ± 6.9, symptoms 
and feelings 2.8; daily activities 
2.2; leisure 1.8; work and 
school 1.5; personal 
relationships 1.6; treatment 1.1 
 
Nasal or pharynx 
involvement 
Positive Nikolsky’s sign 
Higher severity 
Itching 
Skin burning 
Longer disease duration 
Layegh, 
2013[187] 
Iran 
NR 
cross-
sectional 
n=78 PV, 32% newly 
diagnosed 
Males: 40% 
Mean age: 46.98 years 
DLQI 
Total: new patients 12.7 ± 6.4, 
patients with longer disease 
duration 7.7 ± 7.2 
Hospitalised and newly 
diagnosed cases 
Wysoczyńska, 
2013[198] 
Poland 
2010-2012 
case-
control 
n=22 (PV 18 and 
foliaceus 4), 59% of 
patients had disease 
duration >5 years 
Males: NR 
Mean age: 61.6 years 
SF-36 
 
Total: 54.1; PCS 55; MCS 53; 
RP 12.5; RE 33.3§ 
Higher severity  
Physical symptoms (not 
specified) 
DLQI 
Total: 4.0 ± 5.9 Higher severity  
Physical symptoms (not 
specified) 
Skindex-29 
Total: 56.0 ± 23.4 Higher severity  
Physical symptoms (not 
specified) 
Kumar, 
2013[186] 
India 
July 2006-
Sep. 2007 
cross-
sectional 
n=50 (PV 48, foliaceus 2, 
corticosteroid +adjuvant 
therapy) 
Males: 58% 
Age: 52% aged 35-54 
years* 
 
WHOQOL-
BREF 
 
Total: 44.8 ± 4.8; physical 
health 10.8; psychological 
health 12.0; relationships 7.8; 
environment 14.1 
Physical health: Ikeda, 
concurrent psychiatric 
illness, WHODAS 2.0, 
ATT, AI, MADSR, 
IMPACT 
Psychological health: 
disease severity, 
concurrent psychiatric 
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Author,  
year 
Country, 
study 
period 
Study type Patients’ characteristics 
HRQoL 
measures 
HRQoL scores (mean) 
Determinants of 
decreased HRQoL 
illness, WHODAS 2.0, AI, 
MADSR, IMPACT 
WHODAS 
2.0 
Total: 42.2 ± 25.0 Ikeda, concurrent 
psychiatric illness, 
WHODAS 2.0, AI, ATT, 
MADSR, IMPACT, SSQ 
Tabolli, 
2014[195] 
 
Italy 
2012-2013 
cross-
sectional 
n=203 (type not 
specified) 
Males: 42% 
Mean age: 52.7 years 
Skindex-17 
symptoms - with lesions 36.4, 
without lesions 25.6; 
psychosocial - with lesion 42.4, 
without lesions 32.9 
Female 
Presence of skin lesions  
Rajan, 
2014[192] 
India 
Nov. 2011-
Feb. 2012 
cross-
sectional 
n=9 PV 
Males: 56% 
Mean age: males 44.8, 
females 39.3 years 
COMDQ 
Total: 73.6 ± 5.6; pain and 
functional limitation 25.7; 
medication and treatment 17.6; 
social and emotional 22.3; 
patient support 8.3  
- 
* Ghodsi, 2012[185]: inclusion > 12 years; Kumar, 2013[186]: inclusion ≥15 years 
§ In the study of Wysoczyńska, 2012 [198] mean scores of the other six dimensions of SF-36 were not reported. 
** most common comorbidities in the study: hypertension, osteoporosis, diabetes, obesity, glaucoma 
NR: not reported 
For SF-36 and WHOQOL-BREF higher scores refer to a better HRQoL, and for any other measures higher scores represent a worse HRQoL. 
ADLs = Activities of Daily Livings; AI = Anxiety Index; ASQ = Anxiety Scale Questionnaire; ATT = Attitude to Appearance scale; BP = bodily pain; 
CDQ = Clinical Depression Questionnaire; COMDQ = Chronic Oral Mucosal Diseases Questionnaire; DLQI = Dermatology Life Quality Index; GH = 
general health; GHQ = General Health Questionnaire; HRQoL = health-related quality of life; IMPACT = Impact of Skin Disease Scale; MADRS = 
Montgomery-Åsberg Depression Rating Scale; MH = mental health; PF = physical functioning; PGA = Physician’s Global Assessment on disease 
severity; PV = pemphigus vulgaris; RE = role-emotional; RP = role physical; SF = social functioning; SF-36 = Short form-36; SSQ = Social Support 
Questionnaire; VT = vitality; WHOQOL-BREF = World Health Organization Quality of Life-BREF; WHODAS 2.0 = World Health Organization 
Disability Assessment Schedule 2.
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4.2.2 Results of the meta-analyses 
4.2.2.1 Meta-analysis of studies with SF-36 
Five studies were included in the meta-analysis, and all reported SF-36 dimension scores 
on treated and/or hospitalised pemphigus patients [184, 191, 193, 194, 196]. The studies 
of Paradisi et al. (2012) [190] and Wysonczyńska et al. [198] were not included in the 
meta-analysis, because they did not report results for each dimension of the SF-36. The 
study of Timoteo et al. [197] was excluded, as it only reported results graphically. The 
meta-analysis showed the highest deterioration in the role-physical dimension of SF-36 
(38.1, 95% CI 20.4-55.9), followed by role-emotional (47.5, 95 % CI 21.9-73.2), vitality 
(50.7, 95% CI 43.6-57.7) and general health (51.5, 95% CI 45.9-57.0) (Figure 10). 
4.2.2.2 Meta-analysis of studies with DLQI  
Five studies reported a DLQI score in pemphigus patients, with mean scores sitting 
between 4.0 and 13.8 [183, 185, 187, 189, 198]. Four studies were included in the meta-
analysis, all of which enrolled newly diagnosed or untreated pemphigus patients [183, 
185, 187, 189]. Patients in the study by Wysonczyńska et al. were not included in the 
meta-analysis due to 77% of the participants reporting a disease duration of more than 
two years [198]. Newly diagnosed or untreated patients scored on average 12.0 (95% CI 
11.1-12.9) (Figure 11).  
4.2.2.3 Meta-analysis of studies with Skindex-29 
Three studies reported the Skindex-29 dimension scores of medically treated and/or 
hospitalised pemphigus patients [190, 191, 193]. The meta-analysis indicated similar 
mean scores in the symptoms (35.8, 95% CI 32.7-38.9) and emotions (36.5, 95% CI 33.8-
39.2) domains of Skindex-29, whereas they were slightly lower in social functioning 
(32.8, 95% CI 29.9-35.6) (Figure 12).  
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Figure 10 Meta-analysis of SF-36 studies in pemphigus patients 
Random-effects models. Sizes of dots refer to the sample sizes of studies. All studies included treated and/or 
hospitalised pemphigus patients. SF-36 scores range from 0 (worse HRQoL) to 100 (better HRQoL).  
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Figure 11 Meta-analysis of DLQI studies in pemphigus patients 
Total DLQI scores of newly diagnosed or untreated pemphigus patients. Fixed-effects model. DLQI ranges 
from 0 to 30, where higher scores refer to worse HRQoL. Sizes of dots refer to the sample sizes of studies. 
 
 
Figure 12 Meta-analysis of Skindex-29 studies in pemphigus patients 
Skindex-29 dimension scores of medically treated and/or hospitalised pemphigus patients. A random-
effects model was used in the symptoms dimension, whereas a fixed-effects model was employed in the 
emotions and social functioning dimensions. Scores range from 0 to 100, where higher scores refer to a 
worse HRQoL. Sizes of dots refer to the sample sizes of studies. 
4.2.3 Determinants of HRQoL in pemphigus 
Overall, 41 possible determinants of HRQoL in pemphigus were identified, which we 
classified into socio-demographic, clinical, treatment-related and psychological factors 
(Table 11).  
Socio-demographic factors 
Paradisi et al. found that older patients tended to have a decreased HRQoL in the RP, BP 
and RE dimensions of SF-36 and, according to Darjani et al., in total SF-36 scores [184, 
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191]. In contrast, no association between age and any SF-36 or Skindex-29 dimensions 
or DLQI was found in other studies [183, 185, 187, 191, 194, 196]. 
Female patients were found in a significantly worse HRQoL in all dimensions of 
SF-36, with the exception of RP and RE, and in the symptoms and emotions domain of 
Skindex [191, 195]. Another study conducted with SF-36 [194, 196] and three others with 
DLQI reported that gender had no significant effect on HRQoL [183, 185, 187].  
In one study, lower educated patients reported decreased HRQoL in SF-36 [184]. 
In contrast, three other studies observed no relationship between the level of education 
and DLQI or SF-36 scores [185, 187, 194]. Two studies described that patients’ jobs or 
professions influenced SF-36 scores [184, 196]. For example, Darjani et al. found that 
among pemphigus patients in Iran, housekeepers had the worst and farmers had the best 
HRQoL measured by SF-36 [181]. Three studies found that marital status was not 
associated with HRQoL [185, 194, 196]. 
Clinical factors 
Worse HRQoL in SF-36 was linked to longer disease duration, especially in the VT, SF, 
RE and MH domains of SF-36 and in the total DLQI score [183-185, 194]. This is 
supported by the findings of Arbabi et al., who found that patients with recurrent 
pemphigus had significantly higher DLQI scores [183]. Other studies contradict this 
conclusion, when reporting no relationship between disease duration and HRQoL on 
DLQI, SF-36, Skindex-29 or WHOQOL-BREF [183, 186, 191, 196].  
Patients with two or more somatic comorbidities had a lower HRQoL in all 
dimensions of SF-36 apart from SF [191]. A negative relationship between disease 
severity and HRQoL was described in five studies by SF-36, WHOQOL-BREF and 
Skindex-29 [185, 186, 191, 194, 198]. In contrast, the severity of the oral lesions in PV 
patients did not have a significant impact on DLQI [185]. The extension of the skin 
lesions was found in SF-36 to be a significant predictor of social functioning [196]. 
However, Mayrshofer et al. identified no association between the extension of the lesions 
and DLQI [189]. 
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Table 11 Determinants of HRQoL in pemphigus patients 
Determinants of HRQoL 
Number of 
studies 
Total 
number of 
patients 
Negative 
impact 
No impact 
Positive 
impact 
References 
Socio-demographic factors 
Older age  7 641 2 6 0 [183-185, 187, 191, 194, 196] 
Female gender  7 768 2 5 0 [183, 185, 187, 191, 194-196] 
Lower level of education 4 273 1 3 0 [184, 185, 187, 194] 
Employment 2 106 2 0 0 [184, 196] 
Marital status  3 149 0 3 0 [185, 194, 196] 
Clinical factors 
Longer disease duration 7 613 3 4 2 [183-186, 191, 194, 196] 
Higher disease severity 5 317 10 0 0 [185, 186, 191, 194, 198] 
Oral severity 1 61 0 1 0 [185] 
Clinical activity or presence of lesions 2 233 1 1 0 [195, 196] 
Comorbidities 1 126 1 0 0 [191] 
Extension of the lesions 2 57 1 1 0 [189, 196] 
Facial localisation 1 30 1 0 0 [196] 
Nasal or nasopharyngeal localisation 1 61 1 0 0 [185] 
Mucocutaneus lesions 3 245 2 1 0 [185, 191, 194] 
Itching 2 88 1 1 0 [185, 189] 
Skin burning 2 88 1 1 0 [185, 189] 
Pain 1 61 0 1 0 [185] 
Physical symptoms (not specified) 1 22 3 0 0 [198] 
Pemphigus foliaceus 2 184 0 2 1 [191, 194] 
Positive Nikolsky’s sign 1 61 1 0 0 [185] 
Recurrent pemphigus 1 212 1 0 0 [183] 
Number of hospitalisations 1 76 1 0 0 [184] 
Inpatient 1 78 1 0 0 [187] 
Average days spent in hospital 1 30 0 1 0 [196] 
Complications due to pemphigus 1 30 0 1 0 [196] 
Iatrogenic complications 1 30 0 1 0 [196] 
Treatment-related factors 
Adjuvant (+ corticosteroid) vs. corticosteroid  4 345 1 3 2 [184, 190, 191, 196] 
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Determinants of HRQoL 
Number of 
studies 
Total 
number of 
patients 
Negative 
impact 
No impact 
Positive 
impact 
References 
Rituximab (+corticosteroid) vs. corticosteroid  1 113 0 0 1 [190] 
Duration of systemic corticosteroid treatment 1 30 0 1 0 [196] 
Use of other treatment in addition to adjuvant 
(+corticosteroid)  
1 30 0 1 0 
[196] 
Physiotherapy  1 7 0 0 1 [197] 
Monthly cost of treatment during active phase of 
pemphigus  
1 30 0 1 0 
[196] 
Early termination of therapy due to the lack of 
financing 
1 30 0 1 0 
[196] 
Psychological / psychiatric factors 
Concurrent psychiatric disorder 1 50 1 0 0 [186] 
General Health Questionnaire positivity 2 325 3 0 0 [183, 195] 
Anxiety 2 108 2 0 0 [186, 194] 
Depression 2 108 2 0 0 [186, 194] 
Behaviour after the onset of illness 1 50 1 0 0 [186] 
Attitude to appearance 1 50 1 0 0 [186] 
Social support 1 50 1 0 0 [186] 
Coping strategy 1 50 0 1 0 [186] 
The column listing ‘number of studies’ does not always equal the sum of the columns stating ‘negative/no/positive impact’. Bold font rows indicate a clearly significant 
relationship between a certain determinant and HRQoL noticed in at least two separate studies. 
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According to Terrab et al., there was no relationship between disease activity and any of 
the SF-36 dimensions [196], while in another study the presence of the lesions showed a 
significant impact on both the symptoms and psychosocial dimensions of Skindex-17 and 
on the GHQ-12 score [195]. Amongst symptoms, itching and skin burning showed 
significant effects on DLQI in one study but not in another [185, 189]. The presence of 
pain did not influence adversely the DLQI, but a positive Nikolsky-sign did [185]. 
Two studies compared HRQoL between PV and PFo patients [191, 194]. Paradisi 
et al. found a significantly worse health state of PV patients in the symptoms dimension 
of Skindex-29; nevertheless, this was not confirmed by SF-36 scores in this study, or by 
Tabolli et al. [191, 194].  
Mucocutaneous lesions in PV patients were associated with a lower level of 
HRQoL, as assessed by SF-36, especially in the RE, RP and BP domains [191, 194]. By 
contrast, no such relationship between mucocutaneous lesions and total DLQI score was 
proven [185]. Patients with face involvement showed significantly deteriorated total SF-
36 scores, and those with nasal or pharyngeal involvement indicated worse DLQI scores 
[185, 196].  
Hospitalised patients reported higher total scores on DLQI [187]. Furthermore, in 
one study, the higher number of hospitalisations was associated with lower SF-36 total 
scores [184]. Yet, in another study, no relationship was found between the average length 
of hospitalisations and SF-36 [196]. 
Treatment-related factors 
Compared to receiving no treatment or only corticosteroids, patients treated by 
corticosteroid therapy plus traditional adjuvants (e.g azathioprine, cyclophosphamide, 
mycophenolate mofetil) showed significantly improved SF-36 total scores in the study of 
Darjani et al. but a significant deterioration in the PF domain of SF-36 in the study of 
Paradisi et al. [184, 191]. In contrast, no such difference in SF-36 outcomes was noted 
between treatment groups in two other studies [190, 196]. With respect to Skindex-29, 
one study reported significantly better scores in the SF domain in patients receiving 
corticosteroids plus adjuvants, whereas in another study no significant difference was 
present [190, 191].  
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Patients who were treated with rituximab showed significantly higher SF-36 
scores in the RP, VT and MH domains of SF-36 compared to those receiving only 
corticosteroids [190]. In the study of Timoteo et al. seven patients receiving 
physiotherapy improved HRQoL after four months in all dimensions of SF-36 except for 
VT and SF [197]. Neither the duration of systemic corticosteroid therapy nor the use of 
other treatments, cost of therapy or early termination of treatment due to financial issues 
had an impact on SF-36 scores [196]. 
Psychological factors 
The presence of skin lesions compared to quiescent periods or a higher DLQI score were 
associated with the General Health Questionnaire (GHQ) positivity in two studies [183, 
195]. Moreover, patients indicating higher a level of anxiety and depression had 
significantly lower HRQoL scores in both the physical and the psychological domains of 
WHOQOL-BREF and in all dimensions of SF-36, apart from BP (anxiety and depression) 
and PF (anxiety) [186, 194]. Kumar et al. observed that concurrent psychiatric illness, 
behaviour after illness, attitude to appearance and social support all influenced 
WHOQOL-BREF scores, but coping strategy did not [186]. 
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4.2.4 Valuation of pemphigus health states by the general population 
4.2.4.1 Characteristics of the pemphigus study population 
Overall, 115 adults were recruited to the study, three of whom refused to participate in 
the group interviews. Thus 112 questionnaires were completed, of which the TTO tasks 
of four questionnaires were returned blank. Data from 108 respondents were therefore 
analysed. The mean age of the subjects was 26.0±9.1, and there were slightly more 
females (58%) than males (Table 12). Three-quarters of the participants were university 
students. There were no pemphigus patients in the sample, and 97% of the study 
population had never heard about pemphigus.  
Table 12 Characteristics of the general population sample for the pemphigus study 
 N (%) or Mean (SD) 
Number of respondents 108 
Gender  
Female 63 (58%) 
Male 45 (42%) 
Age (years) 26.0 (9.1) 
Education  
Secondary school 24 (22%) 
College/university 84 (78%) 
Employment*  
University student 81 (75%) 
Full-time job 29 (27%) 
Part-time job 26 (24%) 
Retired 2 (2%) 
Other 5 (5%) 
Prior experiences with pemphigus  
Have never heard about it 105 (97%) 
Have read about it on the Internet 1 (1%) 
Know someone with pemphigus 1 (1%) 
Have seen pemphigus patients 1 (1%) 
Have ever been diagnosed with pemphigus 0 (0%) 
*combinations may occur 
4.2.4.2 Visual analogue scale and time trade-off utility results 
The mean estimated VAS scores attached to the PV, PFo and uncontrolled pemphigus 
health states were as follows: 0.25±0.15, 0.37±0.17 and 0.63±0.16, respectively (Table 
13). Corresponding mean TTO utilities were 0.34±0.38, 0.51±0.32 and 0.75±0.31. The 
distribution of TTO utilities is presented in Figure 13.  
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Overall, 14% and 6% considered PV and PFo as being worse than dead 
(utility ≤ 0). The rate of ‘1’ answers was very low for both the PV and PFo health states 
but as high as 26% for controlled pemphigus. There were no non-traders in this study 
(who rated all health states equal to 1). Significant differences were found in both the 
VAS and TTO utilities for all three health states (p<0.001). In each health state, TTO 
utilities were significantly higher compared to VAS (p<0.001). 
Table 13 VAS and TTO utilities for pemphigus health states 
 n 
Mean 
(SD) 
Median 
Range 
(min-max) 
utility ≤ 0 utility = 1 
VAS* 
Uncontrolled PV 107 
0.25 
(0.15) 
0.20 0-0.80 6 (6%) 0 (0%) 
Uncontrolled PFo 107 
0.37 
(0.17) 
0.35 0-0.90 1 (1%) 0 (0%) 
Controlled pemphigus 
(either PV or PFo) 
107 
0.63 
(0.16) 
0.70 0.25-0.99 0 (0%) 0 (0%) 
TTO** 
Uncontrolled PV 108 
0.34 
(0.38) 
0.40 (-1) - 1 15 (14%) 1 (1%) 
Uncontrolled PFo 108 
0.51 
(0.32) 
0.50 (-1) - 1 6 (6%) 4 (4%) 
Controlled pemphigus 
(either PV or PFo) 
108 
0.75 
(0.31) 
0.80 (-1) - 1 2 (2%) 28 (26%) 
TTO - inconsistent answers removed** 
Uncontrolled PV 104 
0.35 
(0.38) 
0.40 (-1) - 1 13 (12%) 1 (1%) 
Uncontrolled PFo 106 
0.51 
(0.32) 
0.50 (-1) - 1 5 (5%) 4 (4%) 
Controlled pemphigus 
(either PV or PFo) 
107 
0.75 
(0.30) 
0.80 (-1) - 1 2 (2%) 28 (26%) 
All three health states differed statistically significantly (Wilcoxon signed-rank test p<0.001) measured by 
either VAS or TTO. 
*VAS utilities in this study range between 0 (worst) and 1 (best). 
**TTO utilities in this study range between -1 (worst) and 1 (best). 
PFo = pemphigus foliaceus; PV = pemphigus vulgaris; TTO = time trade-off; VAS = visual analogue scale 
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Figure 13 Distribution of TTO utilities for the pemphigus health states 
PFo = pemphigus foliaceus; PV = pemphigus vulgaris; TTO = time trade-off 
TTO utilities in this study are ranging between -1 (worst) and 1 (best). 
Male gender and older age were associated with significantly higher utilities for PFo on 
VAS (0.42 vs. 0.34, p=0.024 and r=0.25, p=0.008), but this was not the case for PV or 
controlled pemphigus. More educated respondents tended to elicit higher utilities in PFo 
VAS (0.39 vs. 0.30, p=0.013), PFo TTO (0.54 vs. 0.39, p=0.032) and in PV VAS (0.26 
vs. 0.20, p=0.027). Age or gender had no influence on the TTO responses, and 
employment status had no impact on either VAS or TTO utilities. 
Seven inconsistent answers occurred which were linked to five respondents. The 
most common reason for inconsistency (n=5) was that more than one indifference point 
was marked on the response sheet, with gaps between them (Appendix 12.4). In one case, 
a respondent stopped trading life years and refused further trading, then returned to the 
‘cannot decide’ option (n=1). In yet another case, a participant continued to trade life 
years after reaching the point of indifference (n=1). After the removal of inconsistent 
answers, there were almost no changes in the results (Table 13).
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4.3 DLQI study 
4.3.1 Characteristics of the DLQI study population 
A total of 516 responses were collected in the Internet survey. Overall, 208 participants 
were excluded for the following reasons:  
 15 participants were under the age of 18 years; 
 175 returned the TTO part of the questionnaire blank; 
 18 provided inconsistent answers in all three DLQI health states.  
The responses of 308 respondents were judged valid and included in the analyses. The 
mean age of the study population was 27.4 (min.-max. 18-75) years, with a female 
predominance (69%) (Table 14). Almost half of the respondents reported to hold a college 
or university degree (47%). Overall, 18% of the participants responded to have had a 
dermatological condition diagnosed by a physician at the time of the survey. Non-atopic 
dermatitis (4%), acne (3%) and psoriasis (2%) were among the most frequent diagnoses. 
4.3.2 Time trade-off utility values 
Overall, 124 to 130 individuals assessed each health state, and a total of 882 utilities were 
elicited (Table 15). Mean utilities for the six-point M1, M2, M3 health states were as 
follows: 0.64±0.32, 0.75±0.27 and 0.62±0.30. Mean utilities for the 11-point health states 
were UL1=0.66±0.31, UL2=0.64±0.28 and UL3=0.59±0.29. Health state ‘S’ was assessed 
the most severe with a mean US=0.56±0.29 (Figure 14). The six-point ‘M1’ was valued 
as bad as being dead (i.e. utility=0) by 12% of the respondents, while this rate was only 
5% for ‘M2’. Over 22% of the respondents were not willing to trade time for health state 
‘M2’ (i.e. utility=1). In contrast, this rate was a mere 10% for health state ‘S’. 
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Table 14 Characteristics of the DLQI study population 
 N (%) or Mean (SD) 
Number of respondents 308 (100%) 
Gender (missing n=2)  
Female 210 (68.6%) 
Male 96 (31.4%) 
Age (years) (missing n=1) 27.4 (10.3) 
Education (missing n=2)  
Primary school 1 (0.3%) 
Secondary school 160 (52.3%) 
College/university 145 (47.4%) 
Employment*  
University student 177 (57.5%) 
Full-time job 104 (33.8%) 
Part-time job 48 (15.6%) 
Unemployed 4 (1.3%) 
Retired 3 (1.0%) 
Other 16 (5.2%) 
Medically diagnosed dermatological condition at the time of the survey 
(missing n=1)* 
 
No 253 (82.4%) 
Yes  54 (17.6%) 
Non-atopic eczema 12 (3.9%) 
Acne 8 (2.6%) 
Psoriasis 7 (2.3%) 
Atopic eczema 5 (1.6%) 
Verruca vulgaris 4 (1.3%) 
Rosacea 3 (1.0%) 
Dermatomycosis 2 (0.7%) 
Urticaria  2 (0.7%) 
Other (one respondent per each condition)** 18 (5.8%) 
* combinations may occur 
** acanthosis nigricans, actinic keratosis, clavus, condyloma, dyshidrosis, fibroma, herpes labialis, 
hyperhidrosis, impetigo, keloid, keratosis pilaris, metal allergy, naevi, onycomycosis, photosensitivity, 
seborrhea capitis, trichoepithelioma, vitiligo 
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Table 15 Time trade-off utilities for the health states defined by DLQI 
Health 
state 
DLQI 
total 
score 
N 
Utilities Comparison of health states (p)** 
Mean (SD) Median utility=0 utility=1 L1 L2 L3 M1 M2 M3 S 
Total sample* 
L1 11 124 0.66 (0.31) 0.80 12 (9.7%) 23 (18.5%) - 0.320 0.040 0.683 0.022 0.179 0.003 
L2 11 127 0.64 (0.28) 0.70 9 (7.1%) 13 (10.2%) - - 0.150 0.539 <0.001 0.511 0.012 
L3 11 125 0.59 (0.29) 0.60 7 (5.6%) 14 (11.2%) - - - 0.100 <0.001 0.407 0.370 
M1 6 125 0.64 (0.32) 0.80 15 (12%) 18 (14.4%) - - - - 0.006 0.354 0.009 
M2 6 130 0.75 (0.27) 0.85 6 (4.6%) 29 (22.3%) - - - - - <0.001 <0.001 
M3 6 126 0.62 (0.30) 0.70 12 (9.5%) 21 (16.7%) - - - - - - 0.094 
S 16 125 0.56 (0.29) 0.60 10 (8.0%) 12 (9.6%) - - - - - - - 
Responses of those without any dermatological condition*** 
L1 11 97 0.66 (0.31) 0.80 10 (10.3%) 18 (18.6%) - 0.158 0.022 0.807 0.067 0.191 0.004 
L2 11 105 0.62 (0.28) 0.70 8 (7.6%) 9 (8.6%) - - 0.215 0.217 <0.001 0.993 0.060 
L3 11 105 0.58 (0.30) 0.60 6 (5.7%) 11 (10.5%) - - - 0.038 <0.001 0.201 0.586 
M1 6 108 0.65 (0.32) 0.80 14 (13.0%) 15 (13.9%) - - - - 0.033 0.288 0.006 
M2 6 101 0.74 (0.27) 0.80 6 (5.9%) 20 (19.8%) - - - - - 0.001 <0.001 
M3 6 107 0.62 (0.30) 0.70 10 (9.3%) 16 (15.0%) - - - - - - 0.079 
S 16 100 0.55 (0.30) 0.60 9 (9.0%) 10 (10.0%) - - - - - - - 
* Each respondent assessed three different DLQI-defined health states in a randomised order. The total number of TTO responses was 882. 
**A Mann-Whitney U test p<0.05 was considered significant (in bold).  
*** The total number of TTO responses from participants without any dermatological condition was 723. 
In the names of health states, L refers to large impact on HRQoL, M refers to moderate impact on HRQoL and S stands for the most severe health state.
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Figure 14 Utility values for the seven health states (mean, 95% CI) 
‘M1-3’ refers to a DLQI total score of 6, ‘L1-3’ to 11 and ‘S’ to 16. TTO=time trade-off 
 
4.3.3 Comparison of the utilities 
Overall, 21 pairwise comparisons were made between utilities attached to the seven health 
states: six and 15 between health states of identical and different DLQI total scores, 
respectively. In three cases out of the six comparisons (50%) significant differences were 
observed between utilities for health states with identical total DLQI scores. Regarding 
the 11-point health states (L1-L3), a significant difference was revealed between ‘L1’ and 
‘L3’. There was no significant difference between ‘L1’ and ‘L2’ or between ‘L2’ and 
‘L3’ (Table 15). Among the three six-point moderate health states, significant differences 
were found between ‘M1’ and ‘M2’, and ‘M2’ and ‘M3’, but not between ‘M1’ and ‘M3’. 
The lack of significant difference was noticed in eight out of the 15 comparisons (53%), 
where health states for which the DLQI total score differed greater than for the MCID 
were compared. We found no statistically significant difference between ‘S’ and ‘M3’ 
despite the 10-point difference between these two health states.  
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4.3.4 Impact of any dermatological condition on utilities 
The mean utilities elicited from respondents who had no dermatological condition were 
higher than from those who had no skin problem (0.68±0.30 vs. 0.63±0.29, p=0.029). No 
difference was observed in mean utilities for binocular blindness between these two 
groups (0.49±0.30 vs. 0.50±0.27, p=0.796). For the single health states, the number of 
respondents with dermatological illnesses (n=18-28) was too small to detect a significant 
within-group difference except for health state ‘L2’ (0.75±0.26 vs. 0.62±0.28, p=0.036). 
In a sensitivity analysis, after eliminating the responses of participants with any 
dermatological conditions, only minor changes occurred in mean utilities and in the 
significance of the differences between health states (Table 15). 
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5 Discussion 
5.1 Psoriasis study 
In the ‘Psoriasis study’, we assessed health status, disease severity and HRQoL in a 
consecutive sample of 200 moderate-to-severe psoriasis patients from two Hungarian 
university clinics. As more than half of our patients were treated by systemic biological 
therapy, our sample represented approximately 8% of the total number of psoriasis 
patients received biological therapy in Hungary at the time of the survey [148].  
5.1.1 Health status and HRQoL in Hungarian moderate-to-severe psoriasis patients 
We found notably impaired HRQoL in most EQ-5D dimensions, whilst in addition the 
EQ-5D index scores compared to the gender- and age-matched general population norms 
(Figure 7 and Figure 8). However, patients treated by biologicals experienced 
significantly improved HRQoL. Their mean EQ-5D index score approximated that of the 
general population of the same age (0.75 vs. 0.81), which is consistent with findings from 
large RCTs which proved that biological therapy can considerably improve not only 
clinical outcomes, but also HRQoL [149-151]. Our study therefore provided a clear 
picture of the burden of living with moderate-to-severe psoriasis, as well as the benefits 
of biological therapy. 
Mean EQ-5D index scores of female patients were significantly lower compared 
to their male counterparts despite their similar mean PASI scores (Table 6). No such 
difference was revealed in the EQ VAS or DLQI scores; however, this could be a result 
of the small number of females in the sample. Some prior studies found the same 
association between gender and HRQoL in psoriasis, using DLQI and Skindex-29 [199, 
200], whereas other authors reported that psoriasis affects both sexes equally [127].  
The patients’ age negatively correlated with their actual EQ-5D scores. However, 
deviations away from this trend can be found in Figure 8. Male psoriasis patients’ HRQoL 
was lower at age 18-24 than at 25-34, or at age 55-64 than at age 65-74. Presumably, 
older age is associated with improved coping mechanisms and decreased social rejection, 
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and additionally patients learn how to live with psoriasis and recalibrate their self-
assessment of disability over time and report better HRQoL [201, 202].  
Fifty-seven patients with moderate-to-severe psoriasis associated with psoriatic 
arthritis had a substantially reduced HRQoL. Most earlier studies that reported HRQoL 
in psoriasis associated with psoriatic arthritis enrolled psoriasis patients reporting any 
severity [200, 203, 204]. Neither of these studies applied the EQ-5D questionnaire. 
However, in this group of patients, the efficacy of systemic treatments is particularly 
important to be assessed together, as the real health gain (e.g. expressed in EQ-5D score) 
might exceed that measured in psoriasis or psoriatic arthritis separately. 
The EQ-5D questionnaire was employed in two earlier Hungarian studies 
enrolling patients with skin diseases [121, 122]. Brodszky et al. assessed HRQoL in 183 
psoriatic arthritis patients with a mean age of 50 years and a mean PASI score of 6.5 
[121]. The results of our moderate-to-severe psoriasis patients with psoriatic arthritis 
correspond to their EQ-5D and EQ VAS findings (Figure 15).  
 
Figure 15 Comparison of EQ-5D and EQ VAS scores in moderate-to-severe 
psoriasis, psoriatic arthritis and systemic sclerosis in Hungary 
PsA = psoriatic arthritis; SSc = systemic sclerosis.  
Data sources: Brodszky et al. 2010 [121], Minier et al. 2010 [122] 
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Minier et al. studied 80 systemic sclerosis (SSc) patients (mean age: 57 years), 60 
and 20 of whom had diffuse and limited SSc, respectively [122]. Hungarian SSc patients 
rated their health worse than psoriasis patients without psoriatic arthritis but better than 
those with psoriatic arthritis, as measured by either EQ-5D or EQ VAS. 
5.1.2 Psoriasis patients’ expectations regarding length of life and future HRQoL 
Besides the current health state of patients, we assessed their expectations on subjective 
LE and HRQoL for six months ahead and for future ages.  
Notwithstanding the more than 20-year-long disease duration on average, our 
patients were fairly positive in the short term. They expected an improvement ranging 
from 0.08 to 0.26 in their EQ-5D score. In most patients, this achieved the MCID for EQ-
5D (0.10 and 0.20 for those patients who fulfilled the criteria of PASI25-49 and PASI50-
74, respectively) [205]. A possible reason for their optimistic behaviour is that a high 
proportion of the patients had received biologicals or were about to start their first 
biological drug (56% and 8% of the 167 patients). The introduction of biologicals to the 
treatment of psoriasis has considerably changed the expectations and outcomes of patients 
[206]. The 14 patients at the initiation of their first biological expected on average 
0.18±0.27, which seems quite realistic in the light of the results of the RCTs, in which 
0.12 to 0.21 improvement in EQ-5D was achieved within 12 to 54 [149, 151, 207, 208]. 
This is supported by recent registry-based real-life data on 267 Swedish patients initiating 
their first biological treatment, who improved 0.12±0.24 in their EQ-5D score across 
various follow-up durations (12-52 weeks) [209]. Moreover, in our sample, expectations 
of patients about to start their first biological therapy were in line with the actual EQ-5D 
of patients on biologicals at the time of the survey (0.77 vs. 0.76).  
Only female patients from our study expected to live less time than their statistical 
life expectancy. Multiple comorbidities, particularly the higher risk of cardiovascular 
diseases, may contribute to decreased life expectancy in psoriasis patients. A large 
population-based cohort study conducted before the era of biologicals described that male 
and female patients with severe psoriasis died 3.5 and 4.4 years younger, respectively, 
than those who lived without psoriasis [210]. Recently, however, systemic treatment 
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(either biologicals or methotrexate) has been proven to prevent against cardiovascular 
disease events [211].  
Patients expected a great decline in their HRQoL for the future ages of 60 to 90, 
respectively. This is notably lower than results for the age-matched participants of a 
similar study among the Hungarian general population (Figure 9) [165]. Nonetheless, 
expectations in the long run might be biased by age norms and might not reflect on 
changes of age norms and longevity that have happened in the last 20 years [212]. Thus, 
it can be assumed that patients’ poor expectations are not self-fulfilling prophecies. 
Earlier, a similar study was carried out involving Hungarian rheumatoid arthritis 
patients on the initiation of their first biological drug (n=92, mean age: 51.1±11.9) [166]. 
They expected a 0.39 improvement in their EQ-5D scores within three months compared 
to the average 0.18 improvement within six months expected by psoriasis patients (n=14). 
Yet, very similar expectations can be observed for each future decade with the exception 
of the age of 90, where psoriasis patients expected significantly lower EQ-5D scores.  
5.1.3 Recommendations for future research 
In future studies, it would be useful to assess the HRQoL of mild psoriasis patients also 
from Hungary. Other preference-based measures, such as the TTO, are suggested to be 
employed in this regard. More attention should also be paid to measuring HRQoL in less 
prevalent types of psoriasis (e.g. guttate, inverse and palmoplantar psoriasis), and it would 
be very beneficial to investigate the expectations of younger and newly diagnosed 
patients’ expectations across different time frames. We strongly encourage researchers to 
explore whether the relationship between future expectations and long-term prognosis 
exists, and whether it influences the findings of clinical trials of new interventions.   
5.1.4 Limitations 
Some limitations need to be considered. First, patients were recruited from two university 
clinics in the two largest cities of Hungary, and about half of them were treated by 
biological drugs. No information is available on the health status of untreated patients or 
whether patients treated in other centres are different from these patients. Thus, the 
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external validity of the results may be limited, and our findings may not be generalisable 
to all moderate-to-severe psoriasis patients in Hungary. Secondly, the Hungarian 
statistical LE data used for the comparisons were gender- and age-matched, but other 
socioeconomic determinants, such as the level of education, marital status and monthly 
income, were not adjusted.  
5.2 Pemphigus study 
The ‘Pemphigus study’ consisted of two large parts, namely a systematic review and a 
meta-analysis of the existing literature on HRQoL studies in pemphigus and a valuation 
of utilities for pemphigus health states from the general population. 
5.2.1 Systematic review and meta-analysis 
We performed the first systematic literature review and meta-analysis of HRQoL studies 
in pemphigus. Overall, 16 original papers from eight different countries on five continents 
were found that had assessed HRQoL in 1,456 patients with pemphigus. Two earlier 
reviews dealt with the HRQoL of pemphigus patients, but neither of them applied a 
systematic search strategy or a meta-analysis [213, 214]. In all studies, a great negative 
impact of pemphigus on HRQoL was observed. Compared to healthy controls or the 
general population, significantly lower HRQoL was reported in most dimensions of SF-
36 [184, 191, 194, 196, 198]. 
The meta-analysis indicated a higher mean DLQI score (12.0) than previously 
reported in psoriasis (10.5) or atopic dermatitis (11.2) [3]. Three out of the 16 studies 
compared HRQoL of pemphigus and psoriasis patients, and each reported a similar or a 
significantly lower level of HRQoL in pemphigus than that in psoriasis, particularly in 
the PF, RP and GH domains [186, 191, 194]. Moreover, a recent study described that 
compared to other chronic aphtous diseases (e.g. oral lichen planus, recurrent aphthous 
ulcers), pemphigus patients had the worst HRQoL assessed with COMDQ [215]. These 
findings highlight the severe health loss caused by pemphigus, which might even exceed 
that experienced in other severe chronic dermatological conditions. 
In line with other studies, remarkably high, overall 28% to 78% of patients were 
found GHQ-positive (i.e. GHQ-12≥4 or GHQ-28≥6), thereby indicating a probable non-
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psychotic psychiatric comorbidity, such as anxiety or depression [216-218]. The 
psychological vulnerability of patients is important to consider when selecting a 
treatment, as currently systemic corticosteroid therapy represents a first-line treatment for 
pemphigus, which may induce various psychiatric disorders [46]. Moreover, depression 
and side-effects or corticosteroids may cause suicidal ideations or behaviour in patients 
[219].  
Along with psychological impairment, higher disease severity was the most 
important determinant of decreased HRQoL in pemphigus. However, only PGA and the 
Ikeda-index have been administered in these studies, which are not considered as 
objective and validated severity scoring systems for pemphigus [42, 45]. Consequently, 
in further HRQoL studies, the Pemphigus Disease Area Index (PDAI) or the Autoimmune 
Bullous Skin Disorder Intensity Score (ABSIS) are recommended to be used [43, 44, 220, 
221]. The impact of several other factors on HRQoL, such as age, sex, type of pemphigus, 
disease duration, mucocutaneous involvement, clinical activity, itching, skin burning or 
being treated by adjuvant drugs, cannot be stated clearly and should be investigated 
further. 
5.2.2 Valuation of pemphigus health states by the general population 
As our systematic review illustrated, no study in the literature has reported health state 
utility values for pemphigus. Thus, we carried out a questionnaire-based survey, using a 
preference-based outcome measure to provide health utilities for pemphigus. We elicited 
utilities from 108 participants of the general population, using VAS and TTO.  
We found that utilities for PV were significantly worse compared to PFo, which 
is in accordance with the results provided by Paradisi et al., which compared the HRQoL 
of patients with these two forms of pemphigus by Skindex-29 [191]. However, the 
number of PF patients in their study was very low (n=10).  
Despite the negative utilities allowed in our TTO task, corresponding VAS scores 
were significantly lower (0.25, 0.38 and 0.64). This is comparable to results of a German 
study in a sample of predominantly PV patients [222]. The authors reported that after 11 
months of rituximab therapy, patients’ mean VAS score (assessed by their physicians) 
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improved from a mean 34 to 75 [222]. It is well-known from the literature that VAS 
typically leads to lower utilities than TTO [94]. Several explanations address this 
difference (e.g. in the VAS task participants do not consider the duration of the health 
state, or many people tend to interpret VAS as a percentage of a functioning scale or the 
absence of opportunity cost within the VAS), all of which may support the lower VAS 
scores [92].  
The utility associated with uncontrolled pemphigus was found to be worse than in 
uncontrolled atopic dermatitis (0.64) or psoriasis (0.56), similar to severe scleroderma 
(0.37) but better than severe psoriatic arthritis (0.29) assessed by the general public [100, 
223]. Nevertheless, a comparison of these findings is problematic, because 
methodological variations across studies may exist. For example, the time frame was set 
at 10 years in the current study, whereas participants could trade from their full life 
expectancy in others. Another factor that may hamper such comparisons is that we 
allowed the respondents to consider health states to be worse than dead, and hence utilities 
ranged between -1 and 1. Other authors, on the contrary, did not rate negative values. 
5.2.3 Recommendations for future research 
Very limited literature is available on HRQoL in clinical forms other than PV, and so few 
participants in a study makes it very difficult to detect statistically significant and also 
clinically meaningful differences amongst subgroups characterised by different clinical 
features. In order to improve the awareness about HRQoL impairment related to 
pemphigus, studies including larger patient numbers, preferably multicentre and/or 
multinational, are suggested.  
The use of newly developed disease-specific HRQoL tools, namely the 
Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment of 
Autoimmune Bullous Disease Quality of Life (TABQOL) are recommended [172, 224]. 
These questionnaires proved validity and reliability, and they are very promising for 
serving as endpoints in clinical trials of pemphigus [221]. Furthermore, as pemphigus is 
a life-long disease with flare-ups followed by quiescent periods, longitudinal studies 
would help to explore its disease course in terms of HRQoL.  
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Our utility values were elicited from the general public, so they reflect social 
preferences. These general population values are typically recommended to be used in 
cost-effectiveness analyses, in order to support reimbursement decision-making on health 
interventions [89-91], nonetheless, discrepancies may occur between utilities derived 
from patients and members of the general public (see in details in Chapter 1.3.2). Future 
studies assessing utilities in pemphigus patients with various types and severity are 
recommended. 
5.2.4 Limitations 
Our systematic review has some limitations. First, the various HRQoL instruments 
applied, the different sample sizes and the geographic locations make the comparison of 
these 16 studies less certain. Therefore, the role of most factors affecting the HRQoL of 
pemphigus patients is still unclear. Second, in most cases, HRQoL tools were not applied 
by a sufficient number of studies to conduct a meta-analysis. Third, substantial 
heterogeneity was detected across both the SF-36 and Skindex-29 studies, a proportion 
of which most likely stems from variations in the study populations in terms of age, 
disease duration, sex ratio, clinical type and disease severity. Many studies, however, 
failed to report such data. For instance, the type of pemphigus was unknown or not 
specified in 22% of the patients. 
The utility assessment in pemphigus has limitations, too. First, a convenience 
sample was recruited to the study which was not representative of the Hungarian 
population. However, we found that age, gender and employment status were not reliably 
associated with TTO answers. A higher level of education was related to higher TTO 
utilities. Second, the smallest tradable amount of time was six months. As the rate of ‘1’ 
answers for the controlled pemphigus health state was as high as 26%, the respondents 
might have given up time if smaller units of time, such as a few weeks or even days, had 
been offered. Finally, there were a few inconsistent answers, which may be the 
consequence of the self-completion method (Appendix 12.4). The results, nevertheless, 
did not change after the elimination of these answers (Table 13).  
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5.3 DLQI study 
In this study, we measured utility values using time trade-off method for seven selected 
health states described by the 10 items of the DLQI. We found that health states with 
identical total DLQI scores may be valued as significantly different in their utility scores, 
whereas those that differed more than the MCID may have received equal utilities (Table 
15). These findings have many theoretical implications regarding the use of DLQI as a 
benchmark in clinical and financial decisions. 
5.3.1 Theoretical implications 
As described in detail in Chapter 1.3.2.4 and Chapter 1.3.3, the DLQI currently 
plays the most important role in the management of psoriasis patients. The European-S3 
Guidelines recommend biological therapy to moderate-to-severe psoriasis patients who 
meet (BSA > 10 or PASI > 10) and DLQI > 10 [28, 29]. To be eligible for maintenance 
biological treatment, patients need to demonstrate an at least five-point improvement in 
their DLQI scores for weeks 10 to 16 [28]. Furthermore, in many European countries, 
reimbursement guidelines for biological therapy also involve the DLQI (Table 1). In the 
following, based on these guidelines, three examples are given to illustrate the possible 
consequences of the discrepancies observed between DLQI scores and utilities. 
Example 1 
Let us suppose two patients with moderate-to-severe psoriasis – one of them is in health 
state ‘M1’, while the other is in ‘L2’ (Table 4). The first patient has a DLQI total score 
of 6, while the second has 11. Their HRQoL expressed in utilities, however, is equal 
(0.64) (Figure 14). Assuming they have a similar severity score (PASI >10), only the first 
patient is entitled to receive biological therapy according to the guidelines, in spite of the 
fact that their utility scores are identical. 
Example 2 
Let us assume a patient with moderate-to-severe psoriasis who is in health state ‘S’ 
(DLQI=16) and fulfils the severity scores to be eligible for biological treatment. The 
patient commences biological therapy and as a result of the treatment moves to health 
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state ‘M3’. Thus, the DLQI score for this patient is reduced by 10 points, which exceeds 
twice the MCID. In utilities, however, this improvement yields a mere increase of 0.06 
(p=0.094) (Table 15), implicating that a clinically meaningful improvement in DLQI is 
not necessarily accompanied by significant health gains. 
Example 3 
Let us suppose two moderate-to-severe psoriasis patients with a DLQI total score of 11. 
The first patient is in health state ‘L1’, the other is in ‘L3’ (Table 4). The utility score of 
the first patient is significantly higher (0.66 vs. 0.59, p=0.040) (Table 15). This finding 
has two important implications. First, as ‘L1’ and ‘L3’ only differ in the number of 
negatively affected items and/or the levels of impairment, our results suggest that DLQI 
items might not be weighted equally. This is supported by earlier studies that argued for 
the uni-dimensionality of the DLQI based on findings from Rasch-analyses in psoriasis, 
atopic dermatitis and neurodermatitis [131-133, 135, 136]. Secondly, if they meet 
PASI>10, biological therapy is recommended for both patients (‘L1’ and ‘L3’). However, 
considering the fact that there is a significant difference between their pre-treatment 
utility values, we assume that the average utility gain achieved with biological therapy, 
as well as cost-effectiveness, will vary between these two patients. 
5.3.2 Recommendations for future research 
In future studies, a larger number of DLQI health states is recommended to be elicited, 
preferably from a representative sample of the general population. This would allow one 
to develop a mapping model that could predict utilities for DLQI health states. As we 
found differences between utilities assessed by those with and without any dermatological 
condition, a repeat of this experiment in selected patient populations, especially in 
psoriasis, atopic dermatitis, urticaria, acne and vitiligo, in which the DLQI is most 
commonly used [3], or in a mixed sample of chronic dermatological patients, is suggested. 
This could confirm our findings, as well as identify the preferences of the patients. If 
similar discrepancies were justified between the DLQI scores and utilities derived from 
various patient populations, this would help the development of clinical and financial 
guidelines in dermatology. 
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5.3.3 Limitations 
This study has a number of limitations to consider. First, DLQI is a dermatology-specific 
instrument, and it is assumed to be more sensitive to small but clinically relevant changes 
in HRQoL than the TTO. This may explain in part that utilities for health states that 
differed more than the MCID were not statistically significantly different from each other. 
Secondly, due to the Internet experiment, there was a slight overrepresentation of 
participants with dermatological conditions, as usually people tend to be more interested 
in a survey related to their own illness. But, in a sensitivity analysis, only minor changes 
were observed after excluding these respondents (Table 15). Finally, respondents may 
have considered the description of some health states quite unrealistic and found it 
difficult to imagine, because of the lack of information on the extent of skin lesions, 
involved body parts, appearance of the skin or the type or name of any particular skin 
disease. Nevertheless, adding this information might have biased the results, because 
these aspects are not covered by the 10 items of the DLQI. 
5.4 Implications for decision-making in healthcare 
The three studies in this thesis are united by a common focus on HRQoL and health 
utilities in healthcare decisions made in the field of dermatology. In the past 20 years, 
there have been a number of major advances in the treatment of chronic skin diseases, of 
which biological drugs represent the most prominent example. These treatments, 
nevertheless, account for high costs; for example, in Hungary, the mean annual drug costs 
attributed to moderate-to-severe psoriasis patients receiving biological therapy were 4.01 
million HUF (€14,084) 3 per patient (2014) [162]. Most societies cannot afford to treat all 
patients regardless of the severity of their disease, and so they have to make a decision 
about who to treat or who not to treat. The decision, however, is very complex and 
involves a series of outcomes, including HRQoL.  
For physicians as well as payers, clear cut-off points on HRQoL measures need to 
be implemented to support clinical and financial decisions about treatments. A DLQI 
score of 10 is often considered such a cut-off value in the management of many chronic 
                                                 
3 EUR 1 = HUF 285 (year 2014) 
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skin conditions, such as moderate-to-severe psoriasis. However, the discrepancies found 
between DLQI scores and TTO utilities in our ‘DLQI study’ raise many concerns 
regarding the appropriateness of using DLQI in such judgements (see in detail: 
Chapter 5.3.1). The incorporation of the DLQI into clinical and financial guidelines on 
the treatment of moderate-to-severe psoriasis has undoubtedly been a large step towards 
more effective patient management, because it reflects patients’ perspectives. 
Nevertheless, if the tool is not accurate enough, it can still lead to biases in decision-
making, which may in turn distort the allocation of healthcare resources. Many European 
countries that currently apply the DLQI in their clinical and/or financial guidelines, such 
as the UK, Denmark, Sweden, Hungary and Poland, may be implicated (see more 
examples in Table 1). Thus, based on our findings, the use of the DLQI in clinical and 
financial decision-making can be called into question and needs to be investigated further. 
Overall, in this thesis, a number of distinct utility values were presented for 
pemphigus and moderate-to-severe psoriasis. The low utilities found in these conditions, 
especially in certain clinical subtypes such as pemphigus vulgaris, palmoplantar psoriasis 
and psoriatic arthritis, highlight that severe chronic dermatological diseases may cause 
serious health loss. These findings may have implications for priority setting in health 
policy.  
The HRQoL and utility results from this thesis may help to shape the picture in 
the minds of healthcare policymakers regarding what they think about the burden of 
chronic skin diseases. We found that the effective treatment of psoriasis and pemphigus 
might result in considerable health gains which may, however, stem from a multitude of 
outcomes – only a fraction of which can be captured by disease-severity measures alone. 
By measuring utility values that incorporate many other dimensions of HRQoL, such as 
work capacity, daily activities, relationships, leisure time and mental health, among 
others, greater health gains can be achieved. For instance, psoriasis patients who received 
no systemic therapy, traditional systemic therapy or biological therapy reported mean EQ-
5Ds of 0.65, 0.62 and 0.75, respectively. Corresponding mean annual costs of these 
patients were 0.62 million, 0.68 million and 4.5 million HUF (€2186, €2388, €15,790)4 
[162]. The large differences in utilities between psoriasis patients within these treatment 
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groups, or between the uncontrolled and controlled pemphigus health states, provide 
evidence on the value for money achieved through very costly treatments.  
Both the EQ-5D results in psoriasis and the TTO utilities in pemphigus may serve 
as a basis for formal economic evaluations of health interventions. In many countries, 
including Hungary, new treatments are required to demonstrate cost-effectiveness for 
drug reimbursement decisions. For cost-effectiveness analyses, the HTA guidelines of 
many countries, again including Hungary, prioritise the use of country-specific HRQoL 
data assessed by preference-based measures, particularly the EQ-5D [9, 89-91]. Until our 
studies, locally-relevant utility data were not available either in psoriasis or pemphigus. 
Following two previous studies on rheumatoid arthritis and chronic migraine, we were 
the first to provide TTO utilities for a dermatological condition [225, 226].  
Before our study, there were no utility scores available from Hungary in the field 
of dermatology. Thus, results transferred from other jurisdictions were used for cost-
effectiveness models and decision-making regarding the management of these patients. 
Nonetheless, the actual health statuses and utility values of patients in other countries may 
be different from those in Hungary. Variations perceived in epidemiology, severity of the 
disease, practice guidelines and many other factors suggest the existence of differences 
between countries. Transferring utilities may lead to inaccurate conclusions [227]. Utility 
values from the studies in this thesis are therefore very useful in developing more accurate 
cost-utility models, and eventually for patients to receive treatment covered by health 
insurance. Given the similarities in health systems, the EQ-5D scores in psoriasis can be 
used in other CEE countries until country-specific EQ-5D data are obtained. As we were 
the first to elicit utility values for pemphigus health states in the literature, our utility 
scores may be used in economic evaluations in other countries as well. 
  
DOI:10.14753/SE.2016.1921
 91 
  
6 Conclusions 
This thesis aimed to investigate HRQoL and utility values in chronic skin diseases in 
Hungary. To accomplish this goal, three original studies – two disease-specific 
investigations and a study examining the relationship between DLQI and utility scores – 
were carried out in Hungary between 2012 and 2015 [10-16]. 
6.1 Psoriasis study 
Based on our findings, the following conclusions can be drawn: 
 
1. This is the first study from Hungary specifically, and more broadly from the whole 
Central and Eastern Europe, that has used the EQ-5D questionnaire in psoriasis 
patients. For most age groups, the health status and general HRQoL of moderate-
to-severe psoriasis patients is significantly deteriorated compared to the gender- 
and age-matched EQ-5D population norm in Hungary. Palmoplantar psoriasis and 
psoriatic arthritis are associated with the largest impairment in HRQoL. Patients 
receiving biological therapy demonstrate better HRQoL compared with those on 
any other treatment.  
2. Male patients expect a longer life, while females expect a shorter life compared 
to their statistical life expectancy. Patients’ short-term expectations regarding 
their HRQoL are mainly positive, while a great decline is expected for future ages. 
Expectations are influenced by age, gender, clinical subtype, disease severity, 
current HRQoL and applied therapy. Our findings illuminate a new dimension of 
the lifelong burden experienced by psoriasis patients. 
6.2 Pemphigus study 
6.2.1 Systematic review and meta-analysis 
We provided a comprehensive overview of the current scientific knowledge about 
HRQoL in pemphigus patients. The study pointed out the following: 
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1. Pemphigus patients suffer the most problems in the role-physical dimension of 
HRQoL, followed by role-emotional and vitality. 
2. Overall, 41 possible determinants of HRQoL were identified, amongst which 
clinical severity and associated psychological impairment were revealed as the 
most important. 
3. There is a need for longitudinal studies in order to explore the disease course of 
pemphigus with regard to HRQoL. 
4. No preference-based HRQoL instruments have yet been applied in pemphigus; 
thus, input data are missing to calculate QALYs in cost-effectiveness analyses of 
treatments.  
6.2.2 Valuation of pemphigus health states by the general population 
The main conclusions of the study are as follows: 
1. This study provides the first utility values for pemphigus health states. Our 
utilities may serve as a guide for further utility studies and cost-effectiveness 
analyses. 
2. Pemphigus vulgaris is associated with significantly lower utility values than 
pemphigus foliaceus.  
3. The successful treatment of pemphigus might result in large utility gains, which 
is very promising for future cost-effectiveness studies involving various 
treatments for pemphigus patients.  
6.3 DLQI study 
Given the discrepancies found between DLQI scores and utilities: 
1. HRQoL may differ a great deal between patients whose DLQI total scores are 
identical. 
2. Patients with DLQI scores differing more than the MCID may have identical 
HRQoL expressed in their utilities. 
3. A reduction in the DLQI score may not be associated with significant (or any) 
health gains.  
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As a consequence, the DLQI may distort clinical and financial decisions made during the 
management of chronic skin diseases. 
6.4 General conclusions with policy implications 
This thesis provides important information for clinical decision-making, as well as for 
financing and policymaking in healthcare. First, our results have uncovered concerns 
about the most commonly used HRQoL measure in dermatology, the DLQI. In the light 
of our findings, the use of DLQI for everyday clinical practice may distort many clinical 
decisions made on a daily basis by physicians, such as judging severity or treatment 
effects, hospital admission decisions or treatment selection. Considering the number of 
illnesses in which the DLQI is used, the amount of patients affected worldwide may be 
very large. Furthermore, in certain diagnoses, such as moderate-to-severe psoriasis or 
chronic hand eczema, the DLQI is used to support reimbursement decisions about 
treatments. These decisions might well be biased and thereby compromise the cost-
effective management of chronic skin diseases and the efficiency of healthcare systems. 
This implicates many European countries where financial guidelines on the management 
of chronic skin diseases involve the DLQI. 
Second, our utility values for pemphigus and psoriasis demonstrate evidence on the 
large health losses experienced by patients with chronic skin diseases. Results on 
psoriasis patients’ short-term expectations about their HRQoL have a practical usefulness 
for the management of dermatological patients. In clinical settings, careful consideration 
of overoptimistic expectations regarding the impact of treatments on HRQoL may help 
to avoid healthcare provider disappointment. Conversely, handling pessimistic 
expectations can contribute to an improvement in clinical outcomes. Exploring 
expectations is a way to strengthen the physician-patient relationship.  
Finally, utility estimations from our studies have policy implications. In many 
countries, including Hungary, cost-effectiveness evidence is required for reimbursement 
decisions concerning health interventions. The utility values provided for the pemphigus 
and psoriasis health states in this thesis are key input parameters for cost-effectiveness 
models. The accurate measurement of utilities is crucial, because it greatly influences 
cost-effectiveness estimations, and thus financing decisions about treatments. Our results 
are among the first utility values for dermatological conditions in Hungary, and they 
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represent the basis of local data-driven HTA and healthcare decision-making about 
chronic skin diseases. The availability of country-specific utilities allows one to generate 
health system-specific cost-effectiveness estimates. The growth of such locally-relevant 
data improves the quality of cost-effectiveness analyses and eventually health system 
efficiency. 
We hope that these results from the three empirical investigations in this thesis will 
foster more research in the field, as well as promote discussions and debates about the 
use of HRQoL data for clinical and financial decision-making in dermatology.  
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6.5 New findings of the thesis 
This thesis represents the first thorough investigation of HRQoL and utilities in chronic 
skin diseases in Hungary. Beyond national importance, the three studies contribute new 
knowledge about HRQoL in dermatology. 
Importance on the international level 
1. The discrepancies identified between DLQI scores and utility values question the 
use of the DLQI in clinical and financial decision-making.  
2. We were the first to explore psoriasis patients’ expectations regarding their life 
expectancy and future HRQoL. We explored a number of socio-demographic and 
clinical features influencing the under- and overestimating behaviour. 
3. We conducted the first systematic review summarising HRQoL findings in 
pemphigus. We performed meta-analyses on SF-36, DLQI and Skindex-29 
outcomes. Moreover, a total of 41 socio-demographic, clinical, treatment-related 
and psychological determinants of HRQoL were identified.  
4. We assessed utility values for pemphigus health states for the first time in the 
literature. Our utilities for uncontrolled pemphigus vulgaris, foliaceus and 
controlled pemphigus can be used as a basis of future cost-effectiveness analyses 
of pemphigus treatments. 
Importance for Hungary 
1. Our study was the first to examine the health status and HRQoL of moderate-to-
severe Hungarian psoriasis patients, using the EQ-5D health survey. For most age 
groups, we found significantly lower EQ-5D index scores in moderate-to-severe 
psoriasis patients compared to the general population. Following psoriatic arthritis 
and scleroderma, psoriasis is the third dermatological condition for which EQ-5D 
utilities have been evaluated in Hungary. 
2. We provided the first data on HRQoL benefits of biological therapies for 
moderate-to-severe psoriasis at the national level. 
3. Our studies resulted in the first local utility values in psoriasis (EQ-5D) and 
pemphigus (TTO) in Hungary. After rheumatoid arthritis and chronic migraine, 
pemphigus is the third disease for which country-specific TTO utilities are 
available.   
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7 Summary 
 
This thesis aimed to investigate the effect of chronic skin diseases on health-related 
quality of life (HRQoL) and utility values, with a special focus on issues influencing 
clinical and financial decision-making in healthcare. The core of the work is formed by 
three independent, empirical researches carried out between 2012 and 2015 in Hungary. 
We were the first to assess the health status of psoriasis patients, using the EQ-5D 
for Hungary specifically, and in a broader sense for the whole of Central and Eastern 
Europe. Moreover. This was the first study to explore expectations regarding patients’ 
life expectancy and HRQoL for six months ahead and future ages of 60-90. Significant 
deteriorations in HRQoL were noted in most of the 200 moderate-to-severe psoriasis 
patients compared to the gender- and age-matched general population. In the short term, 
patients were very optimistic regarding their health state, whereas large-scale 
deterioration was expected for each future decade. Expectations were influenced by age, 
gender, clinical subtype, disease severity, current HRQoL impairment or applied therapy. 
As a part of the second study, a systematic review of the existing literature and a 
meta-analysis of studies with Short form-36, Skindex-29 and Dermatology Life Quality 
Index (DLQI) outcomes in pemphigus were performed. Then, we evaluated utility values 
through visual analogue scale and time trade-off (TTO) methodologies for three 
pemphigus health states in a general population sample. This was the first study in the 
literature to elicit utilities for pemphigus vulgaris and foliaceus. Our utility values can be 
used as a guide for future utility studies and cost-effectiveness analyses.  
In the third investigation, we estimated utilities, using TTO for seven different 
health states described by the DLQI for members of the general public. We found 
significant differences between the health states of identical DLQI total scores (in three 
out of the six comparisons) and the absence of significant differences between health 
states differed more than the minimal clinically important difference (in eight out of the 
15 comparisons). The discrepancies found between DLQI scores and utilities raise many 
concerns regarding the appropriateness of using DLQI for clinical and financial decisions. 
The three studies collectively provide new evidence to inform clinicians as well as 
healthcare policymakers about the true burden of chronic skin diseases and the value for 
money being achieved through public expenditure. The main findings evoke many 
questions and call for further research to elaborate the role of HRQoL assessment in 
clinical and financial decision-making in the field of dermatology. 
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8 Összefoglalás 
 
Értekezésem a krónikus bőrgyógyászati betegségek okozta életminőség-csökkenés és 
hasznosság-vesztesség vizsgálatát tűzte ki célul, különös tekintettel az orvos-szakmai és 
finanszírozói döntéseket befolyásoló területekre. A disszertáció három önálló, empirikus 
kutatáson alapul, melyeket 2012 és 2015 között végeztünk. 
Magyarországon és Közép-Kelet Európában is elsőként vizsgáltuk psoriasisos 
betegek egészségi állapotát és életminőségét az EQ-5D kérdőívvel. Nemzetközi szinten 
is elsőként mértük fel a betegek élettartammal és életminőséggel kapcsolatos várakozásait 
egy rövidebb 6 hónapos időtávon, illetve évtizedenként 60-90 éves korukra. Kimutattuk, 
hogy a kutatásba bevont 200 középsúlyos vagy súlyos psoriasisos beteg többségének 
egészségi állapota szignifikánsan rosszabb a hazai – nemben és életkorban illesztett – 
általános populációhoz képest. A betegek rövid távon inkább javulást vártak egészségi 
állapotukban, ezzel szemben idősebb korukra fokozatos mértékű, igen jelentős 
rosszabbodást. A várakozásokat befolyásolta az életkor, nem, psoriasis típusa, 
betegségsúlyosság, aktuális életminőség és az alkalmazott terápia. 
Második kutatásunk részeként szisztematikus irodalomkeresést végeztünk 
pemphigusos betegek életminőségével kapcsolatos tanulmányokra vonatkozóan, továbbá 
metaanalízissel elemeztük az SF-36, Skindex-29 és Bőrgyógyászati Életminőség Index 
(DLQI) eredményeket. Ezután meghatároztuk három, pemphigusszal összefüggő 
egészségi állapot hasznosságát vizuális analóg skála és időalku módszerekkel általános 
populációs mintán. A szakirodalomban elsőként közöltünk hasznosságértékeket 
pemphigus vulgarisban és foliaceusban, melyek későbbi egészség-gazdaságtani 
elemzéseknek szolgálhatnak alapjául. 
A harmadik kutatásban hét különböző, a DLQI kérdőív tíz elemével leírt egészségi 
állapot hasznosságát vizsgáltuk időalku módszerrel, általános populációs mintán. Az 
azonos DLQI összpontszámú állapotok hasznosságértékei hatból három esetben 
szignifikánsan különböztek. A minimális klinikailag fontos különbségnél nagyobb DLQI 
pontszámban eltérő egészségi állapotok hasznossága 15-ből nyolc esetben nem tért el 
szignifikánsan. A DLQI és a mért hasznosság értékek között talált ellentmondások 
megkérdőjelezhetik a DLQI alkalmazását klinikai és finanszírozói döntéshozatalban. 
Kutatásaink új eredményekkel szolgálnak a krónikus bőrgyógyászati betegségek 
okozta betegségteherről, valamint hozzájárulhatnak az egészségügyi erőforrások 
értékalapú felhasználásához. Az eredmények számos új kérdést vetnek fel, és rámutatnak 
további kutatások szükségességére a bőrgyógyászat területén az életminőség értékek 
orvos-szakmai és finanszírozói döntéshozatalban való felhasználását illetően. 
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12 Appendices  
12.1 Appendix – Domains and scoring of HRQoL instruments related to this thesis 
 HRQoL 
instrument 
No. of 
items 
Domains Scoring 
Recall 
period 
Reference 
M
A
U
 
EQ-5D-3L 5 
1. Mobility 
2. Self-care 
3. Usual activities 
4. Pain/discomfort 
5. Anxiety/depression 
Each domain has three response levels (no 
problems, some problems and severe 
problems). Responses are transformed 
into a utility score by the scoring 
algorithm. 
1 week [113, 114] 
G
en
er
ic
 p
ro
fi
le
 i
n
st
ru
m
en
ts
 
SF-36 36 
1. Physical functioning (PF)  
2. Role physical (RP) 
3. Bodily pain (BP) 
4. General health (GH) 
5. Vitality (VT) 
6. Social functioning (SF) 
7. Role emotional (RE) 
8. Mental health (MH) 
Each domain is scored on a scale from 0 
to 100, where higher scores indicate better 
health. Scores of domains 1-4 are 
summarised into a Physical Component 
Summary (PCS) score, whereas domains 
5-8 are summarised into a Mental 
Component Summary (MCS). 
4 weeks [125, 126] 
WHOQOL-BREF 26 
1. Physical health 
2. Psychological health 
3. Social relationship 
4. Environment 
The items give a total score of 26-130, 
where a higher score is indicating a better 
HRQoL. 
2 weeks [228] 
WHODAS-II 36 
1. Cognition 
2. Mobility 
3. Self-care 
4. Getting along 
5. Life activities (household and 
work) 
6. Participation 
The score for each item ranges from 1-5, 
and higher scores indicate greater 
disability. The sum of the scores of the 
items across all domains constitutes the 
total score.  30 days [229] 
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 HRQoL 
instrument 
No. of 
items 
Domains Scoring 
Recall 
period 
Reference 
D
er
m
a
to
lo
g
y
-s
p
ec
if
ic
 i
n
st
ru
m
en
ts
 
Dermatology Life 
Quality Index 
(DLQI) 
10 
1. Symptoms and feelings 
2. Daily activities 
3. Leisure 
4. Work/school 
5. Personal relationships 
6. Treatment 
Each question is scored on a 4-point scale 
(0-3). The total score, obtained by 
summing the scores of the 10 items, 
ranges from 0 to 30 where higher scores 
correspond to worse HRQoL.  1 week [34] 
Skindex-29 29 
1. Emotions 
2. Functioning 
3. Symptoms 
Each question is scored from 0-5. Each 
domain is expressed on a 100-point scale. 
Higher scores indicate a lower level of 
HRQoL. 
4 weeks [137] 
Skindex-17 17 
1. Symptoms 
2. Psychosocial 
Each question is scored from 0-3. The two 
domains have separate summing scores, 
ranging from 0–24 in the psychosocial 
and from 0–10 in the symptom subscale. 
Higher scores indicate a lower level of 
HRQoL. 
4 weeks [139] 
Skindex-16 16 
1. Symptoms 
2. Emotions 
3. Functioning 
Each question is scored from 0-6. 
Mean global index score, as well as each 
single domain are expressed on a 100-
point scale. Higher scores indicate worse 
HRQoL. 4 weeks [138] 
HRQoL = health-related quality of life; MAU = multi-attribute utility measures
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12.2 Appendix – Search terms used in the pemphigus systematic review 
 
Patient 
population: 
pemphigus 
#1 
pemphigus(sh) OR pemphigus(ti,ab) OR bullous skin diseases(sh) OR 
((autoimmune(ti,ab) OR skin(ti,ab)) AND (blistering(ti,ab) OR bullous(ti,ab) 
OR vesicobullous(ti,ab) OR vesicular(ti,ab)) AND (disease*(ti,ab) OR 
disorder*(ti,ab) OR dermatos?s(ti,ab))) 
HRQoL 
related generic 
terms 
#2 
health status(sh) OR health stat*(tw) OR quality of life(sh) OR quality of 
life(tw) OR patient preference(sh) OR preference*(tw) OR utilit*(tw) OR 
questionnaire(sh) OR health survey(sh) OR self report(sh) OR well being(tw) 
OR wellbeing(tw) OR Quality-Adjusted Life Year(sh) OR QALY*(tw) OR 
Quality adjusted life year*(tw) OR Quality-adjusted life year*(tw) OR life 
quality(tw) OR QOL(tw) OR HRQL(tw) OR HRQoL(tw) 
Instruments #3 
EuroQol(tw) OR EQ5D(tw) OR EQ-5D(tw) OR Health Utility Index(tw) OR 
Health Utilities Index(tw) OR HUI(tw) OR SF-6*(tw) OR SF 6*(tw) OR 
SF6*(tw) OR short form 6*(tw) OR shortform-6*(tw) OR short-form-6*(tw) 
OR shortform 6*(tw) OR SF-36(tw) OR SF36(tw) OR SF 36(tw) OR short 
form 36(tw) OR shortform 36(tw) OR shortform-36(tw) OR short-form-36(tw) 
OR RAND 36(tw) OR RAND-36(tw) OR RAND36(tw) OR SF-12(tw) OR 
SF12(tw) OR SF 12(tw) OR short form 12(tw) OR shortform 12(tw) OR 
shortform-12(tw) OR short-form-12 (sh,tw) OR Nottingham Health Profile(tw) 
OR NHP(tw) OR Quality of Wellbeing Index(tw) OR QWB(tw) OR Medical 
Outcomes Survey(tw) OR MOS(tw) OR Rosser(tw) OR WHOQOL-100(tw) 
OR WHOQOL 100(tw) OR World Health Organization Quality of Life 
assessment*(tw) OR WHOQOL-BREF(tw) OR WHOQOL BREF(tw) OR 
Assessment of Quality of Life(tw) OR AQoL(tw) OR DLQI(tw) OR 
Dermatology Life Quality Index(tw) OR Skindex*(tw) 
Methods #4 
standard gamble(tw) OR time trade-off(tw) OR time trade off (tw) OR 
TTO(tw) OR Willingness to pay(tw) OR Willingness-to-pay(tw) OR WTP(tw) 
All HRQoL 
studies 
#5 #2 OR #3 OR #4 
Animals #6 animal(sh) 
Humans #7 #1 NOT #6 
Publication 
type 
#8 letter(pt) OR editorial(pt) OR conference abstract(pt) 
All pemphigus 
HRQoL 
studies 
#9 #5 AND #7 NOT #8 
Search closed: 06/10/2014, Language limits: none 
ab=abstract, pt=publication type, sh=subject heading, ti=title, tw=text word 
Search strategy was based on the recommendations of Paisley et al. [169]. 
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12.3 Appendix – PRISMA flowchart of the selection process  
 
 
 
PRISMA flowchart: Moher et al. 2010 [182]  
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12.4 Appendix – Inconsistencies in self-completed TTO answers 
a) More than one indifference points with gaps between them 
 
b) The point of indifference occurs after the respondent has stopped trading and 
refused further trading 
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c) The point of indifference is followed by trading life years 
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